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ABSTRACT
ANALYSIS OF TUMOR SUPPRESSOR GENES IN TESTIS CANCER
REŞAT ÜNAL
M. S. in Molecular Biology and Genetics 
Supervisor: Asst. Prof. Dr. Işık G. Yuluğ 
August 1998, 97 Pages
At least two classes of genes are involved directly or indirectly in the regulation of 
cell growth and differentiation. One group of these genes, known as tumor 
suppressor genes, is involved in cellular regulation by inhibiting uncontrolled 
proliferation. The most frequent genetic alteration in tumor suppressor genes is loss 
of one of their alleles and this is called “loss of heterozygosity” (LOH). Through 
several studies it is found that LOH in tumor suppressor genes is associated with 
uncontrolled cellular proliferation in many cancers.
Testis cancer is a common cancer among young men. The disease is lethal for 
20-30% of the young patients and the risk of having testis cancer increases in 
industrialized countries. Turkish population is a young population where testis cancer 
might be an important threat. The relation between distinct genetic alterations and 
testis cancer has been studied. LOH studies in testis cancer also have been performed 
however the number of such studies is very low.
In this study the relation between testis cancer and the genes BRCA\, BRCAl and 
PTEN is investigated on 18 tumor samples of 10 individuals by using 8 highly 
polymorphic intragenic and extragenic markers with a PCR based LOH assay. LOH 
in BRCA1 was observed in two tumors of two individuals, and LOH in BRCAl was 
observed in five tumors of two individuals. No LOH was found within the PTEN 
gene where only one intragenic marker was used for studying LOH status.
Ill
ÖZET
TESTİS KANSERLERİNDE TÜMÖR BASKILAYTCI GENLERİN
TANIMLANMASI
REŞAT ÜNAL
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi: Yardımcı Doçent. Dr. Işık G. Yuluğ 
Ağustos 1998, 97 sayfa
En az iki tür gen, doğrudan ya da dolaylı olarak hücre büyümesi ve farklılaşması 
üzerinde rol oynamaktadır. Bu genlerin bir grubu tümör baskılayıcı genler olarak 
bilinmektedir ve hücresel düzenleme görevini, kontrolsüz hücre bölünmesini 
engellemek suretiyle yerine getirmektedir. Tümör baskılayıcı genlerde en sık 
rastlanan genetik değişiklik ilgili genin alellerinden bir tanesinin kayba uğramasıdır 
ki tümör baskılayıcı genler için karakteristik olan bu olay heterozigotluğun kaybı 
(loss of heterozygosity) olarak tanımlanır.
Çeşitli çalışmalar sonucunda tümör baskılayıcı genlerdeki LOH ile birçok kanser 
türündeki kontrolsüz hücre bölünmesini arasındaki bağlantı gösterilebilmiştir.
Testis kanseri genç erkekler arasında sıklıkla görülen bir kanser türüdür. Bu hastalık 
genç hastaların %20-30’unda ölümle sonuçlanmaktadır ve sanayileşmiş ülkelerde 
testis kanserine yakalanma riski artmaktadır. Türk popülasyonu testis kanserinin 
ciddi bir tehdit oluşturabileceği genç bir popülasyondur. Çeşitli genetik değişimler ile 
testis kanseri arasındaki ilişki çalışılmıştır. Testis kanserlerindeki heterozigotluğun 
kaybına ait bazı çalışmalar varolmasına karşın bunların sayısı oldukça azdır.
Bu çalışmada testis kanseri ile BRCAl, BRCA2 ve P7EY genleri arasındaki ilişki 10 
hastaya ait 18 tümör varyantı üzerinde 8 yüksek oranda polimorfık gen içi ve gen dışı 
işaretleyici kullanılarak PCR temelli bir LOH analizi yöntemi ile araştırılmıştır. İki 
hastaya ait iki tümörde BRCAl geninde ve iki hastaya ait beş tümörde BRCA2 
geninde LOH’a rastlanmıştır. Yalnızca tek bir gen içi işaretleyicinin kullanıldığı 
PTEA  ^geninde LOH gözlenmemiştir.
IV
ACKNOWLEDGEMENTS
First of all, I would like to express my gratitude to Asst Prof. Dr Işık G. 
Yuluğ for being with me at all times and under all circumstances both in science and 
in private life, and for providing all the requirements for the completion of my thesis. 
This thesis would never prove to be true without her close interest and corrections. I 
would also like to thank very much Dr. Aydın Yuluğ for helping me with 
photographs.
I would like to thank our chairman Prof. Dr. Mehmet Öztürk for making it 
possible to do my master in such a department with great facilities, for his valuable 
advice and for being available at all times. I also thank Assoc. Prof. Dr. Tayfun 
Özçelik for showing the importance of attentiveness and peevishness both in science 
and in private life.
I thank Dr. Ergiin Pınarbaşı for his moral support at hard times in my first 
days; to Dr. Cengiz Yakicier for his scientific contributions and primers.
I also thank Prof. Dr. Haluk Özen and Prof. Dr. Ayşe Ayhan for providing 
the samples and the clinical data for my work.
I would like to express my deepest gratitude to Prof. Dr. Cihan Öner who 
made it possible for me to work in his laboratory as a special project student during 
my undergraduate education, and for introducing me to the field of molecular 
biology and genetics.
Many thanks to Hilal Özdağ for her sincere friendship and providing 
materials that I was in need of; to Cemaliye Akyerli for letting me to be her big
brother and a good friend and for sharing lots of good things with me; to Arzu Atalay 
for being a good and enjoyable group friend; to Tolga Çağatay for sharing his 
computer, car, papers, and friendship with me; to Tuba Dinçer for all that laughter 
and making me always happy; to Emre Sayan for his close and warm relation, and 
for his sincere and honorary friendship; to Berna Özgelik for friendly chats; to 
Birsen Cevher for her naive and kind behaviour; to Liitfiye Mesci for sharing her 
experience; to Alper Romano and Korkut Vata for their deep philosophical and 
scientific comments; to Çağla Eroğlu and Necati Fındıklı for being good laboratory 
friends; and to Füsun Elvan for enabling my work to proceed in a fast and amusing 
manner. I thank my dear friend Buket Yılmaz for being with me always and sharing 
both my good and bad moments, for showing her sincere friendship and honoraiy 
goodwill all the time, for giving me important clues on the real values in life which 
deserve to be considered, and for making my time here more valuable and amusing 
with her existence. Among the new comers, I thank the lovely facsist Gülayşe İnce, 
the proud novice Bileda Bilican, the polite Tolga Emre, the dear/IsA Öztan who, for 
some reason, thinks I am always busy; and Hani El-Otabi, whom I think is as warm 
as his country, for his help.
Many thanks to Harun Boylu who was always with me with his nice chat all 
the year and to my house friend Tolga Ekmekçi for his help and concern.
I owe my way of life to my dear grandmother Semiha Ayan who was with 
me during the last 14 years, shared all my happiness, always cared for my health and 
appetite, and who made me the center of her life. All the moments that we shared and 
will share are very special. I would like to express my deepest gratitude to my 
grandmother who has the greatest role for my becoming what I am today and who 
enabled this with great devotion for years asking for nothing in return.
VI
I also would like to express my love and gratitude to my dear father Dr. 
Nevzat Ünal who encouraged me for my education and who provided everything to 
complete my master study; to my precious mother Yasemin Ünal whom I always felt 
very close to and could sh^e everything easily, who made me to overcome all the 
obstacles, and whose love and support was always present; to my kind-hearted 
younger brother Mehmet Ünal who always made me feel his joy and charm despite 
the distance, and the happiness of having a brotherhood and, who always managed to 
make me laugh; to Hakan Ünal for whom I feel myself lucky to have. He is the one 
who is always closer to the true than I am with his reasonable approach and 
experienced behaviour despite his young age and who always shared his love with 
me generously.
Finally I would like to thank my uncles Doğan Ayan and especially Erdoğan 
Ayan, also his son Doğan Ayan junior, who always made me feel exceptional and 
gave every kind of support. Special thanks to Uğur Çaçaron and his son İlker Emre 
Çaçaron for his moral support by those long phone calls.
Thank vou ALL from the heart...
Vll
TABLE OF CONTENTS
TITLE
SIGNATURE PAGE
ABSTRACT
ÖZET
ACKNOWLEDGEMENTS 
TABLE OF CONTENTS 
LIST OF FIGURES 
LIST OF TABLES 
ABBREVIATIONS
in
IV
Vlll
xn
XIV
XV
CHAPTER 1. INTRODUCTION
1.1 Tumor Suppressor Genes
1.2 Loss of Heterozygosity (LOH)
1.3 Polymorphism and Polymorphic Markers
1.4 Breast-ovarian Cancer Susceptibility Gene 1 {BRCA1)
1.4.1 Loss of Heterozygosity on Chromosome 17
1.5 Breast Cancer Susceptibility Gene 2 {BRCA2)
1.5.1 Loss of Heterozygosity on Chromosome 13
1.6 Phosphate Tensin Homolog {PTEN)
1
1
3
5
9
11
14
15 
17
Vlll
1.7 Testis Cancer 18
1.7.1 Germ Cell Tumor of Testis 20
1.7.2 Causes of Testis Cancer 21
1.7.3 Cellular Classification and Staging in Testis Cancer 22
1.7.4 Treatment of Testis Cancer 27
1.7.5 Unanswered Questions in Testis Cancer 27
1.8 Molecular Biology and Genetics of Testis Cancer 28
1.9 AIM AND STRATEGY 32
CHAPTER 2. MATERIALS AND METHODS 34
2.1 MATERIALS 34
2.1.1 Reagents 34
2.1.2 Nucleic Acids 35
2.1.3 Oligonucleotides 35
2.1.4 Enzymes 35
2.1.5 Electrophoresis Materials 36
2.1.6 Photography and Autoradiography 36
2.1.7 Radioisotopes 36
2.2 SOLUTIONS 37
2.2.1 General Solutions 37
2.2.2 Solutions for Cold and Radioactive Polymerase Chain Reactions 37
2.2.3 Solutions for DNA Isolation from Blood 38
2.2.4 Solutions for DNA Isolation from Paraffin Embedded Tissue 39
2.2.5 Solutions for Non-Denaturing Polyacrylamide Gel Electrophoresis 39
2.2.6 Solutions for Silver Staining 39
IX
2.2.7 Solutions for Radioactive Labelling 40
2.3 PATIENT INFORMATION 41
2.4 METHODS 43
2.4.1 DNA Isolation from Blood 43
2.4.2 DNA Isolation from Paraffin Embedded Tissue 44
2.4.3 Agarose Gel Electrophoresis and Visualization of DNA Fragments 44
2.4.4 DNA Size Markers 45
2.4.5 Polyacrylamide Gel Electrophoresis 46
2.4.6 Quantification of DNA 46
2.4.7 Polymerase Chain Reaction (PCR) 47
2.4.7.1 Optimization of PCR Conditions 48
2.4.7.2 Cold PCR 48
2.4.7.3 Radioactive PCR 49
2.4.8 Radioactive Labelling of DNA 50
2.4.9 Silver Staining 50
2.4.10 Treatment of Radioactive Gels 51
CHAPTER 3. RESULTS 52
3.1 DNA Isolation 53
3.1.1 DNA Isolation from Peripheral Blood 53
3.1.2 DNA Isolation from Paraffin Embedded Tissues (PET) 54
3.2 Polymerase Chain Reaction (PCR) 55
3.2.1 Optimization of Polymerase Chain Reaction Conditions 55
3.2.2 Cold Polymerase Chain Reaction 56
3.2.3 Radioactive Polymerase Chain Reaction 57
3.3 Non-Denaturing Polyacrylamide Gel Electrophoresis
3.4 Determination Of Allele Loss for Each Marker by Silver Staining 
and/or Autoradiography
3.4.1 Assessment of D17S776 for Loss of Heterozygosity
3.4.2 Assessment of D17S800 for Loss of Heterozygosity
3.4.3 Assessment of D17S855 for Loss of Heterozygosity
3.4.4 Assessment of D17S856 for Loss of Heterozygosity
3.4.5 Assessment of D13S260 for Loss of Heterozygosity
3.4.6 Assessment of D13S267 for Loss of Heterozygosity
3.4.7 Assessment of D13S289 for Loss of Heterozygosity
3.4.8 Assessment of PTEN iov Loss of Heterozygosity
3.5 CONCLUSION
59
60 
60 
62 
63 
65
67
68
70
71 
82
CHAPTER 4. DISCUSSION 83
REFERENCES 90
XI
LIST OF FIGURES
Figure 1.1 Functions of tumor suppressor genes and their role in tumorigenesis 2
Figure 1.2 Mechanisms of loss of wild type allele 4
Figure 1.4.1 The chromosomal locations of chromosome 17 markers 13
Figure 1.5.1 The chromosomal locations of chromosome 13 markers 16
Figure 1.7.1 The histological appearance of normal testis 19
Figure 1.7.3.1 The histological appearance of embryonal carcinoma 23
Figure 1.7.3.2 The histological appearance of seminoma 24
Figure 1.7.3.3 The histogenesis of testis tumors 26
Figure 3.1.1 DNA samples isolated from Peripheral Blood 53
Figure 3.1.2 DNA samples isolated from Paraffin Embedded Tissue (PET) 54
Figure 3.2.1 PCR products of D17S855 and DI7S856 markers 56
Figure 3 .2.2 PCR products of normal and tumor DNA samples 57
Figure 3.2.3 Autoradiography result of radioactively labelled PCR products 58
Figure 3 .4.1.1 The silver stained polyacrylamide gel oiD17S776 alleles 61
Figure 3 .4.1.2 Autoradiography result of radioactively labelled PCR products of
marker D7 75776 62
Xll
Figure 3.4.2.1 The silver stained polyacrylamide gel of D17S800 alleles 63
Figure 3.4.2.2 Autoradiography result of radioactively labelled PCR products
oimstxkQT D17S800 63
Figure 3.4.3.1 The silver stained polyacrylamide gel of D17S855 alleles 64
Figure 3.4.3.2 Autoradiography result of radioactively labelled PCR products
of marker DI7S855 65
Figure 3 .4.4.1 LOH in TEC 93 by Mutation Detection Enhancement (MDE) gel 66
Figure 3.4.4.2 LOH in TEC 99 by non-denaturing polyacrylamide gel 
Figure 3 .4.5 Autoradiography result of radioactively labelled PCR products 
TEC 96 and TEC 97 of marker D13S260
67
68
Figure 3.4.6.1 Autoradiography result of TEC 98 PCR products of marker
D13S267 69
Figure 3.4.6.2 Autoradiography result of radioactively labelled PCR products
o f marker DJ3S267 70
Figure 3.4.7 Autoradiography result of radioactively labelled PCR products
of marker D13S289 71
Figure 3.4.8 The silver stained polyacrylamide gel of PTEN alleles 72
Xlll
LIST OF TABLES
Table 1.3.1 
Tablel.3.2 
Table 1.3.3 
Table 1.3.4 
Table 1.8 
Table 2.3
List of polymorphie markers used in LOH study of testis cancer 7 
Alleles and allele frequencies in D 17S800 and D17S855 markers 7 
Alleles and allele frequencies in D 17S856 and D 13 S260 markers 8 
Alleles and allele frequencies in D13S267 and D13S289 markers 8 
The results of LOH studies in several cancers
Patient Information
Table 3.4.1 Results of LOH study for the marker/)77Л'776 
Table 3.4.2 Results of LOH study for the marker DI7S800
Table 3.4.3 Results of LOH study for the marker D17S855
Table 3.4.4 Results of LOH study for the marker DI7S856
Table 3.4.5 Results of LOH study for the marker DJ3S260
Table 3.4.6 Results of LOH study for the marker DI3S267
Table 3.4.7 Results of LOH study for the marker DJ3S289
Table 3.4.8 Results of LOH study for the marker PTEN
31
42
Table 2.4.7.2 Oligonucleotides synthesized and their optimal PCR conditions 49
73
74
75
76
77
78
79
80
Table 3.4.9 Results of LOH study for the genes BRCA\,BRCA2 and PTEN 81
XIV
ABBREVIATIONS
APC Adenomatous polyposis
APS Ammonium persulphate
AFP Alpha fetoprotein
a-P a-phosphate radioactive labelled nucleotide
BRCAl Breast-Ovarian Cancer Susceptibility Gene 1
Brcal Mouse homolog of BRCA1
BRCAl Breast Cancer Susceptibility Gene 2
Brcal Mouse homolog of BRCAl
bp basepair
T degrees celcius
Ci Curie
CIS Carcinoma In Situ
CR Complete Response
cM CentiMorgan
ddHjO double distilled water
dATP deoxyadenosinetriphosphate
dCTP deoxycytosinetriphosphate
dGTP deoxyguanosinetriphosphate
X V
dTTP deoxythymidinetriphosphate
DNA Deoxyribonucleicacid
DCC Deleted in Colon Cancer
dNTP deoxyribonucleosidetriphosphate
EC embryonal carcinoma
EDTA ethyl enediaminetetra-acetic acid
EX Not alive
EtOH Ethylalcohol
g gram
hCGT Human chorionic gonadotropin
kb kilobase
kDA kilodalton
LOH Loss of Heterozygosity
LH Luteinizing Hormone
LDH Lactate dehydrogenase
mRNA messenger ribonucleicacid
MA.TC Mature Teratocarcinoma
mM milimolar
ml mililiter
MgCl2 magnesium chloride
MCC Mutated in Colon Cancer
MMACA Mutated in Multiple Advanced Cancers 1
i^M micromolar
microliter
N Normal
XVI
OD260 optic density at 260 nanometer
OD280 Optic density at 280 nanometer
PBS Phosphate Buffer Saline
PIC Polymorphism Information Content
PTEN Phosphate and Tensin Homolog
PCR Polymerase Chain Reaction
PET Paraffin Embedded Tissue
pH Negative concentration of hydrogen ions
pmol picomol
RFLP Restriction Fragment Length Polymorphism
RNA Ribonucleicacid
RB {Rb) Retinoblastoma
rpm revolution per minute
SSCP Single Stranded Conformational Polymorphism
SE Seminoma
SDS Sodiumdodacylsulphate
T Tumor
TC T eratocarcinoma
TBE Tris-boric acid EDTA Buffer
U Unit
V Volt
VNTR Variable number of tandem repeat
v/v volume by volume
w/v weight by volume
w/w weight by weight
XVll
CHAPTER 1. INTRODUCTION
1.1 Tumor Suppressor Genes
Today it is known that at least two classes of genes are involved directly or indirectly 
in the regulation of cell growth and differentiation. Acquired or inherited alterations 
of these genes are crucial in the initiation and progression of human malignancies. 
The first group of these genes stimulates cell growth in a positive manner and is 
known as proto-oncogenes. The second group of these genes is tumor suppressor 
genes. The characteristic of tumor suppressor genes is their capability to inhibit 
uncontrolled growth and proliferation of cells. Cells therefore become malignant in 
absence or inactivation of their products.
Tumor suppressor genes often show association with the loss of one chromosome or 
a part of a chromosome which results in the conversion of a heterozygote genotype 
to a homozygote genotype through elimination of one allele of a tumor suppressor 
gene or surrounding marker. The function of tumor suppressor genes and their 
alterations that lead to tumorigenesis is summarized in Figure 1.1
Tumor suppressor genes
Point mutations, deletions, rearrangements, gene conversions
Heterozygosity Homozygosity
Restriction Fragment Cytogenetic PCR Based Methods 
Length Polymorphism Analysis
Figure 1.1: Functions of tumor suppressor genes and their role in tumorigenesis
The existence of tumour suppressor genes is revealed by malignant-nonmalignant 
cell fiision studies. The hybrids formed by this way did not show the malignant cell 
phenotype at first but after the loss of some specific chromosomes in the hybrid the 
malignant phenotype reappeared. Another important characteristic of several tumour 
suppressor genes is the loss of normal alleles, which is termed loss of heterozygosity 
(LOH) (Strohmeyer and Slamon, 1994).
The other property of tumor suppressor genes is their requirement of two separate 
mutational events in order to cause tumor development. This hypothesis is known as 
the two hit hypothesis. One of the mutational events may occur in the germ line and 
the second may then occur sporadically or both these mutational events may occur 
sporadically and cause tumor progression. It is more likely for a tumor to follow a
sporadic mutation in a cell that already contains an inherited mutation rather than two 
somatic independent mutations occurring in a single cell lineage.
The two hit hypothesis has been revealed by the studies of retinoblastoma and 
extended to other tumors to explain the nature of tumor suppressor genes.
1.2 Loss of Heterozygosity (LOH)
LOH is a key pointer for the existence of tumor suppressor genes. In studies where 
DNA polymorphisms close to the RB-\ locus in both hereditary and non-hereditaiy 
tumors were analyzed, it was revealed that a significant difference exists between 
normal cells and tumor cells. The normal cells were heterozygous at many loci 
whereas the tumors were homorozygous at the same loci. The reason for this finding 
was that tumor DNA contained alleles from only one of the two homolog 
chromosomes of interest (Goodrich and Lee, 1993).
The mechanisms that lead to LOH were shown by retinoblastoma studies. The loss of 
a whole chromosome, loss of a chromosome followed by the reduplication that 
results in the generation of three copies of the chromosome, deletion of the wild type 
allele or point mutations are indicated as the possible mechanisms that result in the 
conversion of heterozygosity to homozygosity. The mechanisms that lead to the 
conversion of heterozygosity to homozygosity are summarized in Figure 1.2.
Marker A 1 
Rb
Marker B 1
Loss o f a whole Loss o f a chromosome Deletion o f the Point mutation o f the
chromosome followed by reduplication wild type allele w ild type allele
Samples
N T N T N T N T N T N T N T N T
A B A B A B
Alleles
Markers
Figure 1.2: Mechanisms of loss of wild type allele
DNA sequence variants play important roles in several aspects of genetic 
investigation such as evolutionary and population structure studies, forensic and the 
analysis and the diagnosis of genetic diseases. DNA sequence variants which are 
commonly known as DNA polymorphisms result from mutations and may or may 
not have functional consequences.
1.3 Polymorphism and Polymorphic Markers
Molecular polymorphism studies were restricted to the field of immunogenetics until 
Smithies developed the starch gel electrophoresis in 1955. The first DNA 
polymorphisms observed was restriction fragment length polymorphism (RFLP) on 
Southern blots of genomic DNA. This kind of polymorphism is based on the 
restriction fragment size due to the cleavage or noncleavage of the DNA at particular 
sites caused by single nucleotide polymorphisms. In 1985 Jeffreys defined another 
class of common RFLP in which the restriction fragment length variability is due to 
the variable number of tandem repeats (VNTR). These repeats are named 
minisatellites because of their similarity to the much larger satellite DNA repeats. 
The conventional class of RFLP has generally only two alleles while minisatellites 
show hundreds of alleles per locus. Weber identified another subclass of VNTR 
polymorphism in which the repeat unit consists of only two base pairs. These 
dinucleotide repeats are called microsatellites. The advantage of using microsatellites 
is that they can be easily scored by the polymerase chain reaction. Variability, 
number and relative case of scoring are the most important factors that make the 
microsatellites excellent markers for genetic studies. (Schafer and Hawkin., 1997).
The use of polymorphic markers is especially important in molecular genetic studies 
for several reasons. The co-inheritance of pairs of DNA markers with the genes that 
determine variable phenotypic effects is useful in determination of the genetic 
distances between them. The co-inheritance may also be used in the determination of 
the distance between the marker and the gene responsible for the variable phenotypic 
trait. The DNA probe for a marker may also be used in order to find its physical 
location.
The polymorphic markers are useful when they are informative. Informativeness is 
maximized if the marker has many alleles rather than two. The informativeness of a 
marker is measured by its polymorphism information content (PIC) value. PIC is a 
number between 0 and 1, the closer the value is to 1 the better is the marker. Above 
0.7 is considered as a good value for the heterozygosity of a marker.
The polymorphic markers used in this study and their properties are summarized in 
Table 1.3.1.
Table 1.3.1: List of polymorphic markers used in LOH study of testis cancer.
Marker Amplified Allele number Repeat type Maximum
D17S776 ^
Product Size 
I20bp Dinueleotide
Heterozygosity
0.4000
D I7 m O  i 168-178bp 6 Dinucleotide 0.7433
DI7S855 143-155bp 7 Dinucleotide 0.8220
0178856 1.....228-264i3p 6 Tetranucleotide 0.3891
D13S260 158-I71bp 9 Dinucleotide 0.7800
D13S267 \ 148-162bp . 6 Dinucleotide 0.6900
DI3S289 260-276bp ....8........... . Dinucleotide
PTEN \ 15¥p ''V- Dinucleotide Unknown
The alleles and allele frequencies of the markers are as listed in Tables 1.3.2, 1.3.3 
and 1.3.4.
Table 1.3.2: Alleles and allele frequencies in D17S800 and D17S855 markers
D17S800 D17S855
Allele
2.
3..
4.
Value
i 0'l68klf 
0 170kb
Frequency
0.0500
0.1000
Allele
i.
^  2. . . ■
3.
4.
Value
0.153kb
Frequency
■'" 0.0500 
0.1900
0.172kb
0.174kb
0.4200
0.0700
O.lSlkb
0.149kb
0.1800 
0.1500
5. 0.176kb 0.2300 5. 0.147kb 0.1200
6. 0.178kb 0.1000 6. 0T45kb 0.2600
7. 0.143kb 0.0500
Table 1.3.3: Alleles and allele frequencies in D17S856 and D13S260 markers
D17S856 D13S260
Allele Value Frequency Allele Value Frequency
1. "0.264kb 0.0100 ir'·.· 0 .165kb 0.1071
-  l . r 0,260kb 0.7700 2. 0.163 kb 0,4107
'‘l'256kb ’o.03bo 3 . ' O .nikb 0.1071
4. 0.240kb 0.0500 4. 0.167kb 0.0536
5. 0.236kb 0.1200 O.lblkb 0.1250
6. 0.228kb 0.0100 6. 0.159kb 0.0357
7. 0 169kb 0.0893
8. 0.l58kb 0.0357
9. 0.173kb
Table 1.3.4: Alleles and allele frequencies in D13S267 and DI3S289 markers
DI3S267 D13S289
Allele Value Frequency Allele Value Frequency
1. 0.154kb 0.1731 i . 0.260kb 0.4464
2. O.I48kb 0,4423 0.264kb 0.1964
3. b'iOOkb "”0'2885-""" ................. " o;'276kb " ■..o;o536'··''^ "'..
4. 0.156kb 0.0385 4. 0.274kb 0,0536
5. 0.150kb 0.0385 5. 0.272kb 0.1071
6. 0.162kb 0.0192 6. 0.262kb 0.0714
7. 0".268kb 0 0179
8, 0.270kb 0.0536
1.4 Breast-ovarian Cancer Susceptibility Gene {BRCAl)
The tumor suppressor gene BRCAl is responsible for a significant proportion of 
inherited breast and ovarian cancers (Lu et al., 1996). It is a large gene that spreads 
over approximately 100 kb of genomic DNA and is localized to human chromosome 
17q21.3. It contains 24 exons, 22 of which is responsible for the expression of an 
mRNA in abundant levels in variable tissues such as breast, ovarian, testis and 
thymus. The individuals that have one copy of BRCAl inactivated in their germ lines 
are predisposed to developing breast, ovarian and other malignancies (Scully et ai, 
1997, Feunteun and Gilbert, 1996).
BRCA1 encodes a protein of 1863 aminoacids, which carries a zinc finger domain in 
its amino terminal region (Miki et al., 1994). Today it is known that the product of 
BRCA 1 is required for early embryonic proliferation and development. Because of its 
ability to interact with Rad 51, which is a major component in double strand break 
repair and homologous recombination, it is thought that BRCAl plays an important 
role in the maintenance of genomic integrity (Scully et al., 1997).
BRCA 1 is expressed in normal breast epithelial cells and its product is intact in these 
tissues. In normal cells BRCAl is localized to nuclei. BRCAl is detected in the 
cytoplasm of almost all breast and ovarian cancer cells and is also localized to the 
cytoplasm in normal and tumor tissues other than breast. The expression of BRCA 1 
in other tumor tissues like cervix, bladder, colon has also been shown, and the 
expression of BRCA 1 in these tissues is more aberrant than that in breast cancer 
tissues (Chen et al., 1995). The expression of BRCAl has been shown to be five to
fifteen-folds lower in invasive cancer cells than in normal breast tissue. In adults 
BRCAl is expressed highly in the thymus and testes (Marquis e/ al., 1995) and 
aberrantly in the breast, ovary, uterus, spleen and liver (Wilson ei a l, 1997).
In order to find the biological functions oiBRCAl, mutant mouse models were used. 
In a study where the fifth and sixth exons of BRCA1 gene were deleted in mouse, it 
was revealed that this gene plays a crucial role in the control of the proliferative 
process that occurs in the early embryonic development (Hakem et al., 1996). A 
partial deletion including aminoacids 300-361 of mouse Brcal exon 11 was 
introduced into the genome of the embryonic stem cell. In the case of heterozygosity, 
no effect was observed. However the introduction of the mutation to both alleles 
leads to severe retardation and death of the mouse in early developmental stage. This 
study supported that BRCAl plays an important role in tissue proliferation and 
differentiation (Liu et al., 1996). Mutant mouse models were also used in order to 
analyze the histological alterations caused by mutations. Wild tjq)e and mutant mice 
were obviously distinguishable; the mutant mouse characteristically had a smaller, 
poorly organized abnormal phenotype. In contrast, the wild type embryos exhibited a 
well-organized ectoderm and endoderm. The classification of abnormal phenotype 
was done by dividing it into two distinct groups, one of them less severe than the 
other one. The less severe embryos showed epiblast, primitive streak was not 
detectable, and the parietal and visceral endoderms were very thin. In addition the 
extraembryonic region was poorly organized. The severe class did not appear to 
progress significantly beyond 5.5**^  embryonic day (Hakem et al., 1996).
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LOH in a tumor is accepted as an evidence for the location of tumor suppressor 
genes. Through a study in which the deletions of chromosome 17 were assessed in 
order to measure LOH it was shown that BRCA1 was involved in sporadic breast 
carcinomas. A common region on chromosome 17q of approximately 120 kb 
between two loci within the BRCA 1 was identified to be frequently deleted. By using 
17 polymorphic markers it was revealed that BRCAl is involved in sporadic breast 
carcinomas. THRAl, D17S776, D17S855 and D17S856 markers were 4 out of the 17 
markers used in order to find the LOH status of BRCA 1 in sporadic breast cancers. 
The percentage of the informative tumors that were deleted by LOH for the markers 
THRAl, D17S776, D17S855 and D17S856 was 27%, 30%, 27% and 19% 
respectively. It was concluded that the observed LOH affecting the wild type, 
chromosome in tumors from affected breast/ovarían cancer patients was consistent 
with the hypothesis that BRCA 1 is a tumor suppressor gene (Cropp et al., 1994).
In another study in which the LOH in familial breast carcinomas was studied it was 
revealed that BRCAl on 17q and p53 on 17p might play important roles in the 
etiology of familial breast cancers. The LOH percentage found was 24% in the 
BRCAl locus and 31% in thep53 locus. Chromosome 8q (33%) and 19q (27%) were 
also implied as chromosomes in which the LOH rates were high in sporadic breast 
carcinomas (Lindblom etal., 1993).
Allele losses on chromosome 17 have also been studied in ovarian cancers. 16 
epithelial ovarian carcinomas and 2 benign ovarian adenomas were studied for their
1.4.1 Loss of Heterozygosity on chromosome 17
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LOH status by using four polymorphic probes. A high frequency of allele loss on 17q 
(77%) and lower frequency of allele loss on chromosome 17p (69%) were detected 
(Eccles et a/., 1990).
In the existence of both sporadic and familial epithelial ovarian tumors it was 
revealed that a common region of deletion appeared on chromosome 17q. By using a 
sample size of 32 sporadic and 8 familial epithelian ovarian tumors and 21 
polymorphic loci it was suggested that LOH took place in a high proportion which 
indicated that a distinct tumor suppressor gene from BRCA1 localized on 
chromosome 17q may be involved in tumorigenesis. One of the polymorphic 
markers used in this study was D17S855 and the LOH rate for this marker was 73% 
(Godwin et ur/., 1994).
In order to find the involvement of BRCA 1 in prostate cancer, the LOH status was 
measured in 23 prostate cancer patients by using PCR based methods. Five highly 
polymorphic markers D17S855, D17S856, D17S250, D17S579 and DI7S588 were 
used. The LOH percentage found was 44% in DJ7S855, 40% in DI7S856, 10% in 
D17S250, 10% in DI7S579 and 15% in D17S588. According to these data it was 
concluded that BRCA 1 might have an important role in the pathogenesis of prostate 
cancer. (Gao etal., 1995).
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Fig. 1.4.1 shows the chromosomal location of markers used in LOH studies to 
determine the presence of the BRCA1 gene.
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Figure 1.4.1: The chromosomal locations of chromosome 17 markers
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i. 5 Breast Cancer Susceptibility Gene 2 (BRCA2)
Another gene thought to be involved in breast cancer was identified and named as 
BRCA2. The difference between BRCAl and BRCA2 is that germ line mutations in 
BRCA2 predispose male carriers to an increased risk of breast cancer and female 
carriers to an increased risk of ovarian cancer (Rajan et a l, 1996). Early onset female 
breast cancer cases, increased risks of male breast cancers and also ovarian, prostate 
and pancreatic breast cancers are thought to be associated with BRCA2 (Gayther et 
a l, 1997).
BRCA2 is composed of 10248 nucleotides encoded by 27 exons. The first exon is a 
noncoding exon. BRCA2 encodes a protein of 3418 aminoacids, 383 kDA. (Connor 
et a l, 1997). Most of the exons are relatively small but exons 11 and 12 are very 
large and account for 60% of the entire coding region. BRCA2 is localized on 
chromosome 13q 12-13.
It has been shown that the pattern of expression in BRCA2 is very similar to the 
pattern of BRCAl in multiple fetal and adult tissues and that BRCA2 is expressed 
highly in proliferating cells. It is therefore thought that similar pathways as in 
BRCA1 may regulate BRCA2. BRCA2 is expressed in cellular compartments during 
fetal development. Detectable levels of expression in BRCA2 was observed in the 
spleen, small intestine and placenta. High levels of expression in testis and moderate 
levels in the thymus and ovary were observable (Rajan et al, 1997).
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In order to investigate the function of BRCA2 and its role in predisposing to breast 
and other cancers, targeted mutations were introduced to BRCA2 homologs in mice. 
In Brcct2 (as in Brcal), the inactivation of both alleles resulted in developmental 
retardation and disorganization which lead to the death of mice in early 
embryological development. The onset of phenotypic abnormalities in Brca2 was 
earlier than that in Brcal. Although the phenotypic features and time of death was 
highly variable in Brcal null homozygotes, they were much more uniform in Brca2 
homozygotes (Ludwig et al., 1997).
Developmental expression of BRCA2 in adult tissues and its colocalization with 
BRCA1 were investigated by in situ hybridization studies. By using mouse models it 
was shown that Brca2 mRNA expression in the breast was restricted to the 
epithelium and it was found to be highest in proliferating cellular compartments, 
particularly those undergoing differentiation including the testis, thymus, prostate, 
spleen and liver (Rajan et al., 1997).
1.5.1 LOH on chromosome 13
The evidence that BRCA2 is a tumor suppressor gene came from LOH studies 
that found 30-40% LOH in sporadic breast cancers and 50-60% LOH in sporadic 
ovarian cancers on chromosome 13ql2-13 (Stratton, 1996). Another study in 
which 200 breast tumors were tested for LOH in order to find the involvement of 
BRCA2 in sporadic breast cancer by using 11 highly polymorphic markers such 
as DJ3S260, D13S267 and D13S289 determined that 25-30% of all informative
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cases showed LOH (Cleton-Jansen et al., 1995). BRCA2 was localized to a 6 
centiMorgan interval on chromosome 13ql2-13 by using the same polymorphic 
markers (Wooster et al., 1995). The localization of these markers on 
chromosome 13 is shown in Figure 1.5.1. (Ford and Easton, 1995).
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The discovery of genes involved in tumorigenesis is especially important in 
developing therapeutic strategies for solid tumors. Gliomas are neoplasms that 
account for the vast majority of brain tumors and it was thought that studies of allelic 
loss in gliomas could be important for localizing and cloning the gene which may be 
related with its progression. It was found that deletions on chromosome 10 were 
among the most frequent genetic alterations in glioblastomas. LOH on chromosome 
10 was found to be associated with the progression of glioblastomas (Maier et al, 
1997).
Through the study of LOH at chromosome 10q23 it was found that 75% of all 
informative cases show LOH in glioblastomas and 60% of all informative cases 
show LOH in advanced prostate cancers. In another study in which the Cowden 
locus was assessed for LOH in an interval of 6cM, LOH was observed in 26% of 
informative follicular thyroid adenomas and 11% in Hurthle cell adenomas (Marsh et 
ai.1997).
According to these data it was thought that a tumor suppressor gene might be 
localized in this region. The réintroduction of the deleted part to nude mice resulted 
in suppression of tumorigenicity which supported the suggestion of existence of a 
putative tumor suppressor gene in this region. Finally a candidate tumor suppressor 
gene identified and named as phosphatase and tensin homologue was found to be 
deleted from chromosome 10 (PTEN) or mutated in multiple advanced cancers 
(MMACl). The germ line mutations of PTEN in the three related, inheritable 
neoplastic disorders Cowden disease, Lhermitte-Duclos disease and Bannayan-
1.6 Phosphate and Tensin Homolog (PTEN)
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Zonana syndrome supported the suggestion that PTEN may be a putative tumor 
suppressor gene.
PTEN shares homology with the family of protein tyrokinases as well as with the 
cytoskeletal protein tensia PTEN is classified within the family of dual-specificity 
protein phosphatases that phosphorylate serine, threonine and tyrosine residues 
(Myers et a l, 1997). The family of enzymes, which PTEN is included in, is 
characterized by the presence of a catalytic motif which is located within a conserved 
secondary structure consisting of seven a-helices and ten 3-sheets. PTEN exhibits 
substrate specificity, and prefers extremely acidic substrates.
Many point mutations in PrEiV result in neoplastic disorders. It is thought that this is 
due to the disruption of enzyme activity of PTEN Germ line mutations in PTEN give 
rise to three related distinctive disorders. It was found that PTEN was also mutated in 
advanced prostate cancers and one half of endometrial cancers. Disruptions of PTEN 
in breast cancer and gynecological cancers were found to be rare (Myers et al., 
1997).
1.7 Testis Cancer
It is thought that the development of germ cell cancer is associated with two major 
factors, intrauterine prenatal effects, and postpubertal environmental or infectious 
effects in genetically susceptible individuals. Higher circulating in utero estrogen 
levels were associated with an increased testis cancer risk. Through segregation
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studies it was confirmed that familial testis cancer was caused by a relatively high- 
frequency recessive gene (Oliver, 1998).
Testis cancer develops in young and middle aged men. It is most common in men 
between 15-34 years of age. The disease is lethal for 20-30% of the young patients 
(Bartkova et a l, 1991, Parker 1997, Moul 1997, CancerNet: National Cancer 
Institute). Most testis cancer cases occur sporadically and the lifetime prevalence of 
testis cancer in men is 4.9 per 100 000 (Peng et al., 1993). The incidence of testis 
cancer varies from one population to another and is higher in industrialized countries 
(Vistisen et al., 1997). It has increased two-fold in North and West Europe during the 
past 30 years. (Strohmeyer and Slamon., 1997). The worldwide incidence has also 
doubled in the last 40 years. The incidence of testis cancer presents variation 
according to geographic area. Scandinavia has the highest, while Asia and Africa 
have the lowest incidence of testis cancer. The incidence is intermediate in the 
United States and Germany (Bosl et al, 1997).
Histological appearance of a normal testis is shown in Figure 1.7.1
Figure 1.7.1: The histological appearance of normal testis.
This is the microscopic appearance of normal testis. The seminiferous tubules have numereous germ 
cells. Sertoli cells are incospicuous. Small, dark, oblong spermatozoa are seen in he center of the 
tubules.
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Testis cancer that is highly treatable and curable is divided into two broad groups for 
treatment planning as seminomas where the cure rate exceeds 80% and 
nonseminomas. Nonseminomas are subdivided into choriocarcinomas, embryonal 
carcinomas, yolk sac carcinomas and mixed tumors (Strohmeyer et al., 1997). 
Choriocarcinoma contains the highest and teratoma the lowest risk for metastasis 
(CancerNet: National Cancer Institute).
The serum markers play an important role in the indication of diagnosis and follow­
up of testis cancer. Alpha fetoprotein (APP), human chorionic gonadotropin (hCGT), 
luteinizing hormone (LH) and lactate dehydrogenase (LDH) are the most frequently 
used serum markers to detect tumors too small to be detected by physical 
examination. Although very high levels of serum markers indicate a worse prognosis, 
absence of serum markers does not mean the absence of tumor (CancerNet: National 
Cancer Institute).
1.7,1 Germ Cell Tumor of Testis
The term germ cell tumor of testis indicates that the origin of tumors is primordial 
germ cells (Bosl and Motzer., 1997). Germ cell tumors of men account for a 
biologically complex tumor system (Murty et al., 1994), including the histogenesis 
and relationship of various histological types of testis germ cell tumors (Bartkova et 
al., 1991). It is thought that all histological variants of testis germ cell tumors except 
spermatocytic seminoma are derived from the same precursor called carcinoma in
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situ (CIS) (Jorgensen et al., 1990, Kuczyk et ai, 1996). CIS of the testis is a 
preinvasive lesion that with time progresses into invasive germ cell tumor. The 
conversion of CIS into an invasive germ cell tumor takes approximately five years 
(Bosl and Motzer, 1997). It is thought that CIS cells are malignant cells derived from 
gonocytes during embryonic development. The reason of this suggestion was the 
morphological and immunohistochemical similarities between CIS cells and 
primordial germ cells, which could not be observed in comparison with 
spermatogonia. The observation of CIS in almost all seminiferous tubules adjacent to 
seminoma and nonseminoma testis tumors supports the association between CIS and 
germ cell tumors (Jorgensen et al., 1990).
1.7.2 Causes of Testis Cancer
The most favourite hypothesis that explains the link between the declining sperm 
counts and increase of testis cancer is the concept that estrogen-mimicking chemicals 
damage the fetal germ cells. It is recognized that estrogen-mimicking chemicals act 
transplacentally to effect the germ cells in utero. However, it is thought that other 
mechanisms also contribute to the progress of testis cancer. Studying the 
comparative risks of father-to-son and sibling-to-sibling occurrence of testis cancer 
reveals the importance of genetics in comparison to intrauterine environmental 
influences. Brothers but not father and sons might share an in utero factor such as 
specific maternal hormone levels (Oliver, 1997). Patients with a history of 
cryptorchidism, contralateral testes, gonadal dysgenesis, infertility and undescended 
gonads are under higher risk of progression to testis cancer. (Jorgensen et al., 1990,
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Parker, 1997). Molecular genetics based studies have concluded that loss of tumor 
suppressor genes might be associated with testis cancer.
1.7.3 Cellular Classification and Staging in Testis Cancer
Today it is known that testis tumors arise from two origins, germ cells that account 
for 95% of testis neoplasms and nongerminal sex cord stromal cells.
Although most germinal tumors are aggressive, nongerminal tumors are usually 
benign. The concept that testis germ cell tumors arise from primordial germ cells is 
supported through studies in which the expression of H19 gene was investigated. 
This gene is known to have a well-defined expression during embryonal 
development. It was found that the level of expression of H19 was highly correlated 
with stages of maturation and differentiation in various testis tumors which supported 
a primordial germ cell origin of tumors (Prowse et ah, 1998).
Reflecting their origin in primordial germ cells and their remarkable ability to 
differentiate in vivo, testis tumors are histologically classified into two broad groups 
by the World Health Organization (Bosl and Motzer, 1997). Tumors showing single 
cell type are subdivided into seminomas, embryonal carcinomas, teratomas, 
choriocarcinomas and yolk sac carcinomas. Tumors showing more than one 
histological pattern are indicated as embryonal carcinoma and teratoma with or 
without seminoma, embryonal carcinoma and yolk sac carcinoma with or without 
seminoma, embryonal carcinoma and seminoma, yolk sac carcinoma and teratoma
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with or without seminoma and choriocarcinoma and any other elements. (CancerNet: 
National Cancer Institute). Figure 1.7.3.1 shows the histological appearance of 
embryonal carcinoma.
Figure 1.7.3.1: The histological appearance of embryonal carcinoma
This is the histological pattern of embryonal carcinoma sheets. The blue cells are hying to form 
primitive tubules.
The most common type of germinal tumors is seminomas that account for 30% of all 
germinal tumors. These are divided into three subgroups, as typical, anaplastic and 
spermatocytic carcinomas. A typical seminoma is derived from the proliferation of 
primary germ cells and has a uniform property. Anaplastic seminomas show greater 
cellular and nuclear irregularity with more frequent giant tumor cells and many 
mitoses. Seminomas are most frequent in fourth decade of life. Seminomas may 
contain high mitotic rate (anaplasty), syncytiotrophoblastic giant cells and increased 
human chorionic gonadotropin (hCGTP) levels.
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The histological appearance of seminoma is shown in Figure 1.7.3 .2
Figure 1.7.3.2: The histological appearance of seminoma
cells have an intervening stroma with clear infiltrates. The seminoma cells are large with vesicular 
nuclei, and pale watery cytoplasm.
Spermatocytic seminoma is a rare variant, which has no association with CIS. Its 
relation with other germ cell tumors is unknown. These tumors rarely metastasize 
and are found usually in elderly men.
Nonseminomatous germ cell tumors are usually found in the third decade of life. 
Embryonal carcinomas, teratomas, yolk sac carcinomas and choriocarcinomas are 
classified within this group.
The most undifferentiated cell type is embryonal carcinoma. It has totipotential
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capacity to differentiate into the other nonseminomatous cell types. Embryonal 
carcinomas are more aggressive and lethal than seminomas. Embryonal carcinoma 
cells are capable of synthesizing elevated serum concentrations of hCGT and alpha 
fetoprotein.
Choriocarcinomas are made up of cytotrophoblasts and syncytiotrophoblasts. They 
are rarely pure. They with their association with metastatic diseases and high serum 
concentrations of hCGT are characteristic.
Yolk sac carcinoma is the most common testis tumor in infants and children. It is 
also known as endodermal sinus tumor and occurs frequently in combination with 
embryonal carcinoma in adults.
Teratomas contain somatic cell types of two or more germ-cell layers (ectoderm, 
mesoderm or endoderm). Mature teratomas contain a collection of differentiated cell 
types.
Immature teratomas are tumors with partial somatic differentiation elements where 
of the three germ cell layers are incompletely differentiated and not arranged in 
organoid fashion (Bosl and Motzer, 1997). The histogenesis of testis tumors is 
summarized in Figure 1.7.3.3.
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\Figure 1.7.3.3: The histogenesis of testis tumors
The preinvasive state in which testis cancer is limited to the testis, epididymis, or 
spermatic cord is known as stage I testis cancer. The spread to the retroperitoneal or 
para-aortic lymph nodes in the region of kidney besides testis is defined as stage II. 
This stage is further subdivided as stages IIA (nodes less than 2cm in maximal 
diameter), IIB (nodes between 2 and 5cm in diameter) and IIC (nodes greater than 5 
cm in diameter) Spread beyond the retroperioneal nodes is implied as stage III.
26
It is believed that all cases of CIS will progress sooner or later into a germ cell 
cancer. It is better to treat the disease at the CIS stage because treatment at the later 
cancer stages may include radiotherapy and/or chemotherapy, which have serious 
side effects. The surgical removal (orchiectomy) of the effected testis is proposed as 
the treatment of choice in cases of unilateral CIS if the other gonad has a potential 
for fertility. In the case of patients with testis tumor or CIS of the contralateral testis 
the treatment method of choice is localized irradiation (Jorgensen et al., 1990, 
CancerNet: National Cancer Institute). Chemotherapy is the method of treatment 
used to prevent the dissemination of germ cell tumors. Chemoterapy results in a 
complete response (CR) in 70%-80% of patients whereas 20%-30% still dies from 
this disease (Motzer et al., 1990). The risk for relapses in stage I seminomas accounts 
for 4%, for stage IIA and stage IIB 10%. Chemotherapy cures more than 90% of 
patients who have a relapse after radiation therapy. (Bosl and Motzer, 1997)
1.7.4 Treatment of Testis Cancer
1.7.5 Unanswered questions in testis cancer
There are still many problems that seem unsolved. The reason why two age peaks 
exist in testis cancer, and how and why undescended testes, gonadal dysgenesis, 
androgen insensitivity increase the risk of testis cancer is not known. It is also not 
answered whether chemotherapy and radiotherapy are the right treatment strategies 
in terms of fertility (Ginsburg, 1997). The genetic basis of testis cancer has not been 
enlightened enough to answer all the questions.
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Through cytological studies on testis cancer, t was revealed that isochromosome 12 
i (12p) presence is the most common and frequent chromosomal abnormality in testis 
cancer cases. This finding is present in up to 100% of all germ cell tissues studied. It 
is thought that isochromosome 12 appearance is an early event during oncogenesis. 
Other alterations such as trisomies, duplications, deletions and other rearrangements 
for chromosomes 1, 11, X and Y were also shown by cytological studies. It is 
revealed that several proto-oncogenes and growth factors are localized to the 
chromosomes, which are frequently altered in germ cell tumors. Using 
immunohistochemistry and flow cytometry, it was found that low levels of c-myc 
protein product p62 are observable in normal testicular tissue whereas high levels are 
present in seminoma tumor tissues. It was shown that the expression of p62 is 
increased due to the increase in cell differentiation in nonseminomas and the germ 
tumor cell line Tera-2. The incidence of ras mutations was found to be low 
(Strohmeyer et al., 1994). It has been also shown that N-ras and Ki-ras mutations do 
exist in testis tumors and the expression of c-myc and c-kit oncogenes are high in 
germ cell tumors of testis (Shuin et al., 1993).
It was revealed that frequent allelic losses take place in chromosomes 2p, 3p, 3q, 5p, 
9p, 9q, lOq, lip , 12q, 13q, 17p, 17q, 18p, 18q in testis tumors (Murty eta/., 1994/
APC, MCC, DCC, TP53, RB and WT-\ tumor suppresor genes were also investigated 
for their LOH status in a high number of tumors and tumor cell lines of testis by 
using PCR-based methods. 28% LOH was observed at APC, 30% at RB, 23% at
1.8 Molecular Biology and Genetics of Testis Cancer
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MCC, 27% at WT-\ and 22% at TP53 (Peng et al., 1995). p53 is a tumor suppressor 
gene that is most frequently deleted in a variety of human tumors. Although the 
differential expression oîp53  in testis cancer was shown, mutations oîp53 in germ 
cell tumors of testis are not reported (Chou et al., 1997).
In order to find the role of p53 in testis cancer, p53 mutations in both sporadic and 
familial testis cancer samples were assessed. Mutation detection was performed by 
using two efficient screening methods, constant denaturing gel electrophoresis and 
single stranded conformational polymorphism. No mutation was found in p53. It is 
thought that other tumor suppressor genes instead of p53 may play a role in the 
development of testis cancer and that p53 might mediate toxin damage to sperm 
count (Peng et al, 1993). In contrast to most solid cancers, p53 was found to be 
unmutated in testis cancers. However, Kuczyk et a l was able to show mutational 
band shifting at the p53 gene locus in 12 out if 18 (67%) samples by using a sensitive 
assay called RNA-single stranded conformational polymorphism assay (RNA-SSCP) 
(Kuczyk eta l 1996. Oliver, 1997).
In 1994 Murty et al. reported that DCC gene was frequently deleted in male germ 
cell tumors. Using germ cell tumors and tumor cell lines of testis resulted in the 
study concluded that LOH at 18q21 was characteristic of seminomas as well as in all 
subsets of nonseminomas (Murty et al., 1994).
The number of families with multiple numbers of testis cancer cases is low and 
those, which are reported, contain only two affected members. In a study in which 35 
families with two affected sibs were typed by using 220 microsatellite markers, six
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regions were found as candidates for a testis cancer susceptibility gene. The physical 
location of these regions are lp36, 4pl3-14, 4cen-ql3, 5ql2-21, 14ql3-q24.3 and 
18q21.1-q23 (Leahy eta/., 1995).
Some LOH studies performed in order to determine the LOH status in several 
cancers are given in Table 1.8.
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Table 1.8: The results of LOH studies in several cancers
Gene Sample Size % LOH Reference
P53 22%
APC 44 28%
MCC Testis cancer 23% Peng eial., 1995
DCC 55%
WT-1 27%
RB 30%
23 44%
BRCAl Prostate D17S855 Gao et al., 1995
cancer 40%
D17S856
THRAl
130 27%
sporadic DJ7S776 Croppy/a/., 1994
BRCAl breast cancer 30%
D17S855
27%
78
BRCAl Familial 12-19%
P53 breast 16-33% Lindblom et a i, 1993
carcinomas
20 THRA 1
Sporadic 79%
BRCAl breast D17S250
carcinomas 50%
DI7S579
Futreal et al., 1992
59%
50
BRCAl Sporadic 47-67% Poster et a i, 1996
ovarian
Cancer
38 26%
PTEN Sporadic follicular Marsh et al., 1997
thyroid thyroid
Tumors adenomas
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1.9 AIM AJVD STRATEGY
This project aims to determine the status of three candidate genes on chromosome 17 
(BRCAl), 13 (BRCA2) and 10 (PTEN) for loss of heterozygosity in order to identify 
potential tumor suppressor genes, which may be involved in testis tumors. We got 18 
histological tumor variants of 10 testis patients. We wanted to analyse these 18 tumor 
with highly polymorphic dinucleotide and tetranucleotide repeat markers by using a 
PCR-based LOH assay.
The strategy we used was as follows;
♦ This study has been set up in collaboration with Hacettepe University Medical 
School, Department of Urology and Department of Pathology.
• The patients have been examined and operated at Department of Urology and 
their tumor samples were sent to pathology department for analysis. 
Nonseminoma IIC and IIIC patient groups were selected for molecular genetic 
analysis.
• The normal and tumor tissue sections of patient samples were fixed into paraffin 
blocks at pathology department. The sections of samples were cut and dissected 
under the microscope to separate normal and different variants of tumor tissues.
* These samples were send to Bilkent University, Department of Molecular 
Biology and Genetics for molecular analysis in PBS solution.
* The tissue samples were stored at -70°C until they were used. DNA was isolated 
from dissected tissue samples and used to investigate LOH status of different
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genes. Peripheral blood DNA was also isolated and used to optimize the PCR 
conditions.
The PCR conditions for radioactive and normal PCR were optimized to obtain 
the PCR products of our interest.
The PCR products were run in nondenaturing polyacrylamide gels in order to 
separate the alleles.
Depending on the method used autoradiogram or silver staining was performed to 
observe the alleles and decide whether allele loss had occurred or not.
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CHAPTER 2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Reagents
The reagents Tween 20, phenol, chloroform, isoamylalcohol, ethidiumbromide, boric 
acid, acetic acid, formaldehyde, sodium hydroxide, formaldehyde, bromophenol 
blue, xylene cyanol, glycerol, silver nitrate and DMSO were from Sigma Chemical 
Co. (St.Louis, U.S.A)
Tris-Cl and Tris-Base were from Stratagene (Heidelberg, Germany). EDTA and 
sodium hydroxide were from Carlo Erba (Rodano, France). Sodium acetate was from 
Merck (Darmstadt, Germany). Ethanol was from Delta Kim. San. (Istanbul, Turkey). 
Hexa Labe Labelling Kit was from MBI Fermentas Inc. (N.Y, U.S.A).
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100 bp DNA ladder, H infl digested 0x174 DNA and pUC mix marker were used as 
DNA molecular weight standards in this study. All these molecular weight markers 
were from MBI Fermentas Inc. (N.Y, U.S.A). Ultrapure deoxyribonucleotides were 
from Pharmacia (Vienna, Austria).
2.1,2 Nucleic Acids
2.1.3 Oligonucleotides
The oligonucleotides used in polymerase chain reaction were synthesized in the 
Beckmann Oligo lOOOM DNA synthesizer (Beckmann Instruments Inc. CA, U.S.A) 
at Bilkent University, Department of Molecular Biology and Genetics (Ankara, 
Turkey).
2.1.4 Enzymes
Rnase A was from Sigma Chemical Co. (St.Louis, U.S.A). Proteinase K was from 
Appligene-Oncor (U.S.A). Taq DNA Polymerase and Klenow fragment of E.coli 
DNA Polymerase I large fragment were purchased from MBI Fermentas Inc. (N.Y, 
U.S.A).
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Agarose, acrylamide, bisaciylamide, N-N-N trimethylethylenediamine (TEMED), 
ammonium persulfate (APS) were obtained from Sigma Chemical Co. (St.Louis, 
U.S.A).
Horizontal electrophoresis apparatus was from Stratagene (Heidelberg, Germany). 
The power supply used was Power-PAC300 from Bio Rad Laboratories (CA, 
U.S.A). The vertical gel apparatuses used for polyacrylamide gel electrophoresis 
were Bio-Rad Proteon II xi Cell from Bio Rad Laboratories (CA, U.S.A) and EC 175 
Adjustable Vertical Gel System from E.C Apparatus Co. (FL, U.S.A)
2.1.5 Electrophoresis Materials
2.1.6 Photography and Autoradiography
The UV transilluminator was from Herolab. The video graphic printer UP-890CE 
was from Sony Corporation (Japan). Polaroid film UP 110 HD was from Sony 
Corporation (Japan). The films used for autoradiography were from Kodak 
Corporation (U.S.A). Cassettes and intensifying screens were from Amersham 
International (England). Photographic fixer and developer were from Kodak 
Corporation (Japan).
2.1.7 Radioisotopes
a  -^^P- dCTP (3000 Ci/mmol) and a-^^P- dATP (3000 Ci/mmol) were from Orbital 
Ltd.Sti. (Istanbul, Turkey).
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2.2 SOLUTIONS
2.2.1 General Solutions
EDTA;
IxTris-boric acid-EDTA (TBE): 
Ethidiumbromide:
lx Gel loading buffer:
10% SDS 
Tris-Cl 
Proteinase K:
IM, pH 8.0
45mM Tris-borate, ImM EDTA 
10 mg/ml in water (stock solution)
30 ng/ml (working solution)
0.25% bromophenol blue, 0,25% xylene 
cyanol, 50% glycerol, ImM EDTA 
0. Ig/ml in water (stock solution)
0.5M, pH 8.0
20mg/ml proteinase K in water (stock solution) 
lOpl (lOmg/ml) proteinase K was used for each 
DNA isolation reaction.
2.2.2 Solutions for cold and radioactive polymerase chain reactions
dNTP mix (stock solution): lOOmM each of four different kinds of 
dNTP (dATP, dTTP, dCTP, dGTP) 
were mixed to a final concentration of 
0.2mM
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Radioactive PCR dNTP mix (stock solution):
dATP reduced dNTP mix (stock solution); 5mM dATP, lOOmM dTTP
lOOmM dGTP, lOOmM dCTP
dCTP reduced dNTP mix (stock solution): lOOmM dATP, lOOmM dTTP
lOOmM dGTP, 5mM dCTP
MgCl2 (stock solution): 25mM MgCli
lOx PCR Buffer: lOOmM Tris-Cl (pH 8.8) 
500mM KCl. 0.8% Nonidet P40
2.2.3 Solutions for DNA Isolation from blood
20x SSC; 3M NaCl, 0.3M trisodium citrate, pH 7.0
TE buffer: 
Extraction buffer:
lOmM Tris, pH 8.0, ImM EDTA, pH 8.0
lOmM Tris-Cl, pH 8.0 
lOmMEDTA, pH 8.0 
0.5% SDS
Sodium acetate; 3M, pH 5.2
Phenol/chloroform/isoamylalchol: 25:24:1 (v/v/v)
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2.2.4 Solutions for DNA Isolation from paraffin embedded tissue
Digestion buffer: 50mM Tris-CI, pH 8.0 
ImM EDTA 
1% Tween 20
2.2.5 Solutions for non-denaturing polyacrylamide gel electrophoresis
Polyacrylamide; 40% (w/v), Acrylamide/bisacrylamide,
19:1 (w/w), (stock solution)
500ml 40% stock solution preparation; 500mlx40% = 200g (w/v)
200x19/20 =190g Acrylamide was added into 200x1/20 =10g Bisacrylamide and 
dissolved in 500ml deionized water.
Ammonium persulfate: 10% APS in water
2.2.6 Solutions for silver staining
Developer solution;
Fixative solution:
Silver-nitrate:
1.5%NaOH 
0.1% Formaldehyde 
10% EtOH 
0.5% Acetic acid 
0.1% AgN03
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2.2.7 Solutions for radioactive labelling
10 X Reaction buffer: 500mM Tris-Cl(pH 8.0)
dNTP mix: lOmM dATP, lOmM dTTP 
lOmM dGTP, lOmM dCTP
Mix C: dNTP mix minus dCTP
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The patients selected for this study were nonseminoma stage IIC and niC patients. 
18 histological tumor variants of 10 individuals were used for the study.
The detailed information about the patiens is summarized in Table 2.4
The abbreviations for the Table 2.4 are as follows;
NT: No Information
SE: Seminoma histology
TC; Teratocarcinoma Histology
YS: Yolk Sac Tumor Histology
MAT.TC: Mature Teratocarcinoma Histology
EX: Not Alive
2.3 PATIENT INFORMATION
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Table 2.3: Patient Information
Patient code Age Diagnosis date Histologj' PET Sample Last prognosis STAGE Chemotherapj^
Chemotherapy 
before sample 
dissection
Chemotherapy after 
sample dissection
TEC91 • N1 N1 NI NI N1 NI N1 NI NI
TEC93 32 (EX) 22/10/87 TC+EC : 23/10/87 5/6/88 m e + —
TEC94 15(EX) 25/3/83 EC 25/3/83 28/12/83 n e + -
TEC95 29 11/12/87 EC+YS 17/12/87 1/2/89 lie + ■' +
TEC96 44 25/11/89 TC+SE+
EC
4/12/89 21/8/91 n e "4-
TEC97 54 13/7/91 SE4-EC 13/7/91 29/12/95 n e : + ■l· -
TEC98 51 3/9/86 TC+YS 8/9/86 30/6/95 n e ■f
TEC99 39 26/8/89 MAT.TC 22/8/89 25/1/90 n e + + -
TEClOO 30 13/1/89 TC 14/10/89 15/7/90 n e + + -
TEClOl 53 4/11/81 EC 6/11/81 5/2/82 m e + -
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2.4 METHODS
2.4.1 DNA Isolation from blood
700|il blood samples were aliquoted into 1.5ml eppendorf tubes and frozen. The 
samples were thawn and DNA isolation was performed by 
phenol/chloroform/isoamylalcohol extraction. SOOpl IxSSC was added to wash the 
samples. The samples were then centrifuged at 13,000 rpm for one minute and the 
supernatants were removed and discarded. 1.4ml lx SSC was added and after a brief 
vortex the samples were centrifuged for one minute. After the removal of 
supernatant, SOOpl extraction buffer was added into the tubes. This step was followed 
by the addition of lOp,! (lOmg/ml) Proteinase K. The tubes were vortexed briefly and 
incubated at 56°C for one hour. 400pl phenol/chloroform/isoamylalcohol was added 
into the tubes and the tubes were vortexed for 60 seconds. The upper aqueous layer 
formed after a five-minute centrifugation was removed and transferred into new 
tubes. The phenol/chloroform/isoamylalcohol extraction step was repeated in order 
to get a clean interphase. DNA was precipitated from the aqueous solution by 
addition of l/20‘^  volume 3M sodium acetate and 2 volumes ice-cold absolute 
ethanol. The tubes were mixed and placed at -20'^C for 30 minutes and then 
centrifuged at 13,000 rpm for 30 minutes at 4°C. The pellet was washed with 70% 
ethanol, air-dried and resuspended in approximately 25 pi deionized water.
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The paraffin embedded tissue sections were placed into 1.5ml eppendorf tubes and 
stored at -70°C. The tubes were treated with SOOpI digestion buffer. This step was 
followed by the addition of 15p.l (lOmg/ml) Proteinase K. The samples were 
incubated overnight at 55°C. The next day an equal volume of 
phenol/chloroform/isoamylalcohol was added into the tubes which were then 
centrifuged for 10 minutes at 5,000 rpm. The upper layers were transferred into new 
tubes and 2|i.l RNase A was added to the samples. The samples were incubated at 
37°C for 30 minutes. An equal volume of phenol/chloroforoform/isoamylalcohol was 
then added into the tubes and the centrifugation step was repeated. After the 
centrifugation, the top layers were collected and 2.5 volume ethanol and 0.1 volume 
sodium acetate were added to precipitate the DNA samples. The samples were left at 
-20'^C for one hour and centrifuged at 13,000 rpm for 30 minutes. Ethanol was air- 
dried and the DNA samples were resuspended in 25p.l double- distilled water.
2.4.2 DNA Isolation from paraffin embedded tissue
2.4.3 Agarose Gel Electrophoresis and Visualization of DNA fragments
DNA fragments were fractionated by horizontal gel electrophoresis using standard 
buffers and solutions (Maniatis, 1989). Agarose, the amount of which was 
determined according to the required percentage, was completely dissolved in lx 
TBE buffer. The agarose concentration varied between 0.8% and 2% (w/v) to 
maximize the resolution of fragments. Ethidiumbromide was then added at a final 
concentration of 30|j.g/pl. The samples were mixed with one volume loading buffer
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and loaded onto gels. The gel was run in lx TBE at different voltages and times 
depending on the size and the fragment separation required. The DNA fragments 
were visualized under ultraviolet light.
2.4.4 DNA Size Markers
The length of the DNA fragments was determined by using commercially available 
DNA size markers, 100 bp DNA ladder, <J)xl74///ir>^I or pUC mix.
Fragment sizes were as follows;
100 bp DNA ladder: (kb) ' 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.08
0x174/77/«/!; (kb) 0.726, 0.713, 0.553, 0.5, 0.427, 0.417, 0.413, 0.311, 
0.249,0.2, 0.151,0.14, 0.118,0.1
pUC mix: (kb) 1.116, 0.883, 0.692, 0.501, 0.489, 0.404, 0.331, 0.242, 
0.19,0.147, 0.111,0.110
Ikb DNA ladder (kb) 10.0, 8.0, 6.0, 5.0, 4.0, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5
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Electrophoretic separation of polymorphic alleles was performed by the following 
method:
8%-10% polyacrylamide gels were used. 40%(w/v), 19;l(w/w) polyacrylamide stock 
solutions were diluted to the required percentage with lx TBE buffer. The gel 
apparatus was assembled according to the manufacturer’s instructions (Bio Rad 
Laboratories, CA, U.S.A and E.C Apparatus Co., FL, U.S.A).
In order to prepare an 8% gel, lOpl acrylamide;bisacrylamide (19;l,w/v), Spl 
lOxTBE, 200ul TEMED and 40p,l 10% APS were mixed and poured into the gap 
between two glass plates. The polymerization of the gel takes about 15-25 minutes. 
The gels were pre-run for 30 minutes. The samples were mixed with one volume­
loading buffer and loaded into the wells. The gel was run in lx TBE at 250V for 
different time periods (6-8 hours) depending on the size of the fragments at room 
temperature. The gel was then removed and either stained with silver nitrate or dried 
for autoradiography.
2.4.5 Polyacrylamide Gel Electrophoresis
2.4.6 Quantification of DNA
Concentrations and purity of nucleic acids were determined by measuring 
absorbance at 260nm and 280nm in a spectrophotometer (Beckmann Instruments 
Inc., CA., U.S.A). The ratio between absorbance values at A260 and Ajso was taken.
46
Nucleic acid samples displaying ODjeo and OD280 values in the range of 1.8 to 2.0 are 
regarded as highly pure.
A value of A260 = 1 .0  corresponds to a concentration of approximately 50p.g/pl 
double stranded DNA and 20|ig/pl for oligonucleotides. (Maniatis).
The molar extinction coefficient of oligodeoxynucleotides was determined to 
estimate the accurate concentration. The oligonucleotide sequences were entered to 
the spectrophotometer and the concentration was determined.
The concentration of the oligonucleotides was determined by using the equation;
A260 = E (n s G+ n s C+ n s T+ n s A) C 1 
A260 is the absorbance at 260 nm.
C is the concentration in mM.
1 is the path length in cm.
E is the sum of all the mM extinction coefficients of the nucleotides present 
n is the number of bases.
The mM extinction coefficient (s) values for the nucleotides are as follows; 
sdG TP= 12.01 
s dCTP = 7.05 
sdATP = 15.20 
s dGTP = 8.40
2.4.7 Polymerase Chain Reaction (PCR)
Both cold and radioactive polymerase chain reactions have been used in this study.
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PCR conditions were optimized by changing the annealing temperatures, MgCli, 
DNA and primer concentrations. The optimum conditions required for PCR were, 
1.5mM final concentration of MgClj, Ipmol/pl primers and variable annealing 
temperatures between 55-60‘^C. The DNA samples were diluted 10 times and used 
for PCR reactions.
2.4.7.1 Optimization of PCR Conditions
2.4.T.2 Cold PCR
Polymerase chain reactions were performed using Perkin-Elmer 2400 or 9600 PCR 
machines (Perkin Elmer, U.S.A). Standard conditions were Ipmol/pl of each primer, 
200uM final concentration of dNTP, lx PCR buffer, 1.5mM final concentration of 
MgCE and lU Taq DNA Polymerase for each reaction in 25pi final volume. The 
PCR conditions were as follows:
The initial denaturing was at 95°C for 5 minutes and the final extension was at 72^C 
for 5 minutes for all the primer pairs. 35 cycles of PCR reactions were carried out, 
each one beginning with an initial dénaturation step at 94°C for 30 seconds and 
finishing with a polymerization step at 72®C for 30 seconds. The temperatures for the 
annealing step varied between 55-60°C. The PCR conditions are summarized in table 
2.4.7.2.
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Table 2.4.7.2: Oligonucleotides synthesized and their optimal PCR Conditions
GENE-MARKER PRIMER SEQUENCE (5’-3’)
ANNEALING
TEMPERATURE
PRODUCT SIZE
D 1 7 S 7 7 6 F TCCATGACCCTATGGACCA 55“C . .
D 1 7 S 7 7 6 R AAACCTCTGTCTCTITGCAG 120bp-130bp
D I7 S 8 0 0 R GGTCTCATCCATCAGGnTT 55"C
D 17 S 8 0 0 R ATAGACTGTGTACTGGGCATTGA 168bp-178bp
D 1 7 S 8 5 5 F GGATGGCCTTTTAGAAAGTGG 56°C
D I7 S 8 5 5 R AG ACAG ACTTGTCGTACTGCC 143bp-155bp
D I7 S 8 S 6 F AAGGCAAGACTTCGTCGAGA 5 8 T
D I7 S 8 5 6 R CATTCCCTGGTCCTGTGC 228bp-264bp
P T E N F AAATGTACGGTTC ATTGACTT 58°C
P T E N R GACTGACTACAAATGGGCA 154bp
D 1 3 S 2 6 0 F A G A fA ffG T C tcC G T T C C A rG A 55°C
D 13S 260R CCCAGATATAAGGACCTGGCTA 158bp-171bp
D I3 S 2 6 7 F GGCCtGAS^GGTATCCf C 5 5 T  .
D 13S 267R TCCCACCATAAGCACAAG I48bp-162bp
D 1 3 S 2 8 9 F CTGGTTGAGCGGCATT 5 7 “G
1 D 13S 289R TGCAGCCTGGATGACA 260bp-276bp
2.4.7.3 Radioactive PCR
Radioactive PCR amplifications of DNA were carried out as described above with 
some modifications. O.OSpl ” P-dATP (3000 Ci/mmol) or ^^P-dCTP (3000 Ci/mmol) 
was added into each 25pl reaction, and the concentration of the non-radioactive 
dATP or dCTP was reduced to 125|j,M final concentration (I.25mM stock solution 
concentrations). Other conditions were optimized as described previously.
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2.4.8 Radioactive labelling of DNA
DNA was labelled by the random oligonucleotide-primed synthesis method based on 
the random primer method developed by Feinberg and Vogelstein.
Approximately 80-100ng DNA was used for the labelling reaction. DNA, lOpl 
hexanucleotide in 5x reaction buffer (dilution was made from the commercially 
available lOx reaction buffer) and 42pl ddHiO were mixed in a 1.5ml eppendorf tube. 
The tube was then vortexed and centrifuged for 5 minutes. The mix was boiled for 10 
minutes and centrifuged quickly. Then, 3pl MixC (dNTP mix minus dCTP), 4p,l ^^ P- 
dCTP and 1 |il Klenow fragment (DNA polymerase I large fragment) were added to 
the reaction. The reaction tube was centrifuged for 5 seconds and incubated at 37°C 
for 10 minutes. After that, 4ul dNTP mix was added and the tube was left for final 
incubation at 37‘^C for 5 minutes. Finally the reaction was terminated by the addition 
of IplO.SM EDTA, pH 8.0.
2.4.9 Silver Staining
Silver staining was one of the methods which was used initially in this study to 
investigate the loss of heterozygosity (LOH) status. The protocol was as follows;
The gel was washed two times with ddHjO for one minute and then treated two times 
with lx fixative solution for 3 minutes and washed with ddHjO. The next step was 
staining for 9-10 minutes with 0.1% silver nitrate solution. The silver nitrate solution
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was discarded and the gel was rapidly washed twice with deionized water. This is a 
critical step, which is to be done as quickly as possible. After this step the gel was 
treated with ice-cold developer solution. The development of the gel takes 
approximately 1-1.5 hours. The gel was placed into 7.5% acetic acid solution for 15- 
20 minutes. The acetic acid solution was then removed and the gel was stored at 
room temperature between two transparency sheets.
2.4.10 Treatment of radioactive gels
The gel containing radioisotope-labelled PCR products was dried for 
autoradiography. The gel was next placed over a layer of Whatman paper and 
covered with stretch film. It was then placed into the gel drier and dried for two 
hours at 80°C under vacuum. The stretch film was removed and the dried gel was 
placed into a cassette containing intensifying screens. An x-ray film was placed over 
the gel and left for exposure for 9-10 hours. The film was then developed.
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CHAPTER 3. RESULTS
The most recent method used frequently to investigate allele losses is known to be 
PCR-based LOH Assay. According to this method DNAs are extracted from the 
source of interest and fractionated by agarose gel electrophoresis to check whether 
isolation has occurred or not. These samples are then used to amplify the highly 
polymorphic markers localized very close or within the gene selected for investigation. 
After the amplification the products are separated by polyacrylamide gel 
electrophoresis that has a high resolution and visualized by autoradiography or silver 
staining. Finally due to the whole allele loss or intensity reduction it will be concluded 
whether LOH has occurred or not.
The method used in this study was also PCR based LOH assay and the order of the 
experimental design was same as mentioned above.
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3.1 DNA Isolation
3.1.1 DNA Isolation from Peripheral Blood
In the beginning of the study DNA was isolated from peripheral blood. It was planned 
to obtain the tumor tissues of the patients whose blood samples were already present. 
Therefore, DNA isolation of 94 samples was performed. The isolation protocol 
worked with high efficiency and enabled the isolation of most of the DNA samples 
intact and with good yield. The DNA samples isolated from peripheral blood are 
shown in Figure 3.1.1.
1 2 3 4 5 6  7 8 9  10 11
23.0kb
9.4kb
Figure 3.1.1 DNA samples isolated from Peripheral Blood
The DNA samples were run on an 0.8% agarose gel. The DNA size marker is lambda DNA digested 
with H in d  III (Lanes land 11). The other lanes contain the samples as follows;
2: TEC45, 3: TEC 46,4: TEC47, 5:TEC48,6:TEC49, 7: No sample, 8: TEC50, 9: TECl, 10:TEC5.
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3.1.2 DNA Isolation from Paraffin Embedded Tissues (PET)
The tumor tissue samples used in this study were originally embedded into paraffin 
blocks. The isolation of DNA from paraffin embedded tissues was much more difficult 
in comparison with that of DNA from peripheral blood. It is thought that this might 
depend on the age of the paraffin embedded sample, the fixative used, or both.
The main problem in isolating DNA from paraffin-embedded tissue was the inability to 
obtain the genetic material intact. DNA runs as smears on the agarose gel 
electrophoresis and this indicates the degradation of high molecular weight genomic 
DNA. Therefore DNA samples isolated from paraffin-embedded tissues were diluted 
before they were used for further applications. In conclusion it was found that 
degradation of DNA was not a severe problem in order to use it for further 
applications. The DNA samples isolated from paraffin embedded tissue, are shown in 
Figure 3.1.2.
1 2 3  4 5  6 7 8  9 10 11
2.0kb
1.5kb
l.Okb
0.5kb
Figure 3.1.2 DNA samples isolated from Paraffin Embedded Tissue (PET)
The DNA samples were run on an 0.8% agarose gel. The DNA size marker is Ikb ladder (Lanel). 
The other lanes contain the samples as follows;
2: TEC93N, 3: TEC93T1, 4; TEC93T2, 5:TEC93T3, 6:TEC94N, 7: TEC94T, 8: TEC95N,
9: TEC95T1, 10:TEC95T2, 11.TEC96N. (N: Normal tissue, T: Tumor Tissue).
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3.2.1 Optimization of Polymerase Chain Reaction Conditions
Polymerase Chain Reaction is a method to ampliiy a DNA fragment. It basically 
consists of three steps which are dénaturation, annealing and extension. In the 
dénaturation step double-stranded DNA becomes single-stranded in order to provide a 
template to which oligonucleotides will bind. The second step is the annealing step in 
which the annealing temperature plays a much important role. The write annealing 
temperature is important for oligonucleotides to bind to template DNA and avoid the 
unspecific amplifications. The last step is extension in which the polymerization of 
DNA samples takes place. Here the primer or magnesium chloride concentrations or 
the amount of Taq DNA polymerase are the critical factors that make the amplification 
reaction successful. To find optimal conditions in terms providing good amplification 
patterns is defined as optimization of PCR conditions.
In this study DNA samples isolated from peripheral blood were used to find the 
optimal PCR conditions for several polymorphic markers. In the beginning appropriate 
annealing temperatures were investigated for specific amplifications. The annealing 
temperatures of the primers were first calculated according to base content and a 
temperature interval was determined for each primer. By trying the amplification of the 
DNA within this temperature interval, the annealing temperature for each primer was 
found.
3.2 Polymerase Chain Reaction (PCR)
Primer concentrations were determined to find the right primer amount that should be
used for PCR reactions. PCR reactions were performed by using 20pmol and 25pmol
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of primers per reaction. The PCR amplification by using 25pmol primer concentration 
per reaction was found to be the appropriate primer amount. Then the magnesium 
chloride concentration was assessed for an optimal amplification. PCR reactions were 
performed in which l,5mM, 2mM and 2,5mM of magnesium chloride concentrations 
were used. l,5mM of magnesium chloride was found to be sufficient for a specific 
amplification. The total reaction volume was determined as 25pl and 1 unit Taq DNA 
Polymerase was found to be sufficient for a good PCR reaction. 1% DMSO as a final 
volume was used in order to prevent the unspecific product amplifications. The PCR 
products which were obtained by optimized PCR conditions for the markers D17S855 
and D17S856 are shown in figure 3.2.1.
249bp
200bp
ISlbp
140bp
228-264bp
143-155bp
Figure 3.2.1 PCR products oiD17S855 and D17S856 markers
The size marker is (|)X174 (Lane 1). Lane 2 and lane 6 are the negative controls for D 1 7 S 8 5 6  and 
D 1 7 S 8 5 5  respectively. Lanes 3, 4 and 5 contain the PCR amplification products when l.SmM, 2.0mM  
and 2.5mM magnesium chloride concentration were used for D 1 7 S 8 5 6  respectively. Lanes 7 and 8 
contain the PCR amplification products when l.SmM and 2.0mM magnesium chloride concentration 
were used for D 1 7 S 8 5 5  respectively.
3.2.2 Cold Polymerase Chain Reaction
Once the optimal PCR conditions for each primer set of polymorphic markers were 
determined, paraffin-embedded tissue samples were used for PCR amplification.
56
Although DNA samples from PET were degraded, the specific PCR product bands 
could be observed by agarose gel electrophoresis. In conclusion successful 
amplification could be performed with PET. An example of PCR amplification 
products of normal and tumor PET samples by using primers for D17S856 marker are 
shown figure 3.2.2
M arker Negative 97N 97T 99N 99T
311bp
249bp
200bp
^ 28bp
Figure 3.2.2 PCR products of normal and tumor DNA samples
The PCR products were run on an 2% agarose gel. The marker used is <t>X174 (Lane 1). Lane 2 is the 
negative control o f PCR reaction. The other lanes contain the PCR products o f the paraffin embedded 
normal and tissue samples o f TEC97 and TEC99 respectively. The marker used for amplification was
D 17S 856 .
3.2.3 Radioactive Polymerase Chain Reaction
Silver staining can be used to observe the separation of alleles with high resolution. 
However autoradiography is a much more sensitive method for observing the alleles.
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Autoradiography requires the radioactive labelling of PCR products by using one of 
the dNTPs radioactively labelled in the PCR mixture.
Although optimal conditions for radioactive PCR resemble that of cold PCR, some 
differences exist between two conditions. The main difference is the amount of dNTP’s 
used in these two PCR methods. Deoxyribonucleosidetriphosphate stock solutions 
were prepared in which the concentrations of dCTP and dATP were reduced. The 
reason for preparing these stock solutions was to promote the introduction of 
radioactive labelled dCTPs and dATPs to the polymerization of the template DNA 
strand instead of unlabelled deoxyribonucleosides. This application resulted in the 
generation of PCR products which could be observed with autoradiography.
Figure 3.2.3 shows the first example of radioactively labelled PCR products which 
were run on an 8% non-denaturing polyacrylamide gel.
178bp
168bp
Figure 3.2.3 Autoradiography result of radioactively labelled PCR products
Lane 1 and 4 contain the PCR product of TEC49 normal DNA isolated from peripheral blood. This 
sample was used as a positive control. Lanes 2, 3, 5 and 6 contain PCR products of DNA samples 
TEC94 normal tissue (Lane 2 and 5) and TEC 94 tumor tissue (Lane 3 and 6) isolated from paraffin 
embedded tissues. The first three lanes contain PCR products which were labelled with a-P^"-dCTP. 
In the next three lanes the samples were labelled with a-P^^-dCTP. The amplified marker was 
D 17S 800 .
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Polyacrylamide gel electrophoresis is a method used for different aims. It can be used 
in order to study proteins, to detect mutations or to dissociate alleles of DNA. The 
basic principal in order to fulfil all these aims is the movement of proteins or nucleic 
acids fi'om the negatively charged to the positively charged pole. The advantage of 
using polyacrylamide gels is that it provides the high resolution of genetic or protein 
products.
In this study, nondenaturing polyacrylamide gel electrophoresis was used to investigate 
whether allele losses had occurred or not by employing several polymorphic markers. 
Silver staining or autoradiography enabled observation of the samples that were run on 
polyacrylamide gel. All markers were studied for their allele loss by silver staining or 
autoradiography. Polyacrylamide used in this study was prepared as 40% stock 
solution. Before being poured to the electrophoresis apparatus it was diluted to 8% 
and 200j.ll ammonium persulphate (APS) and 40jil triethylmethylendiamine (TEMED) 
were added to the working solution. The polymerization of gels takes about 15-25 
minutes.
3.3 Non-Denaturing Polyacrylamide Gel Electrophoresis
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3.4 Determination of Allele Loss for Each Marker by Silver Staining and/or 
Autoradiography
The reason of choice of radioactivity was its high sensitivity to enable observation of 
alleles in comparison to silver staining. Some of markers were assessed only by silver 
staining some only by autoradiography and some by using both methods.
3.4.1 Assessment of D17S776 for Loss of Heterozygosity
D17S776 is an intragenic marker, which means that it is localized within the gene 
BRCAl. Its loss is shown in several types of urogenital cancers. Although the 
maximum heterozygosity rate of this marker is not very high the intragenic property of 
this marker makes it one of the markers of choice for LOH studies. The loss of 
intragenic markers might result directly in loss of alleles. That is why the intragenic 
markers are important in studying allele losses.
There is no information about alleles and allele frequencies of this marker. The 
maximum amplified sequence also is unknown. It is known that the length of PCR 
products of marker D17S776 varies between 120bp-130bp.
Both silver staining and autoradiography were used in this study in order to study 
LOH. 13 tumors of 9 individuals were studied. In three individuals the PCR 
amplification of five tumors could not be obtained and therefore LOH status could not 
be determined. By silver staining it was revealed that the alleles were amplified in these
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samples studied and they were in expected sizes. Both alleles for all samples existed in 
all samples studied. In conclusion it was found that no loss of allele occurred in marker 
D17S776.
Figure 3.4.1 shows the silver stained polyacrylamide gel result where the alleles for 
marker DJ7S776 were separated after PCR reaction.
1 2 3 4 5 6 7  8
’-'I
130bp
120bp
Figure 3.4.1.1 The silver stained polyacrylamide gel of D17S776 alleles
The PCR products of marker D 1 7 S 7 7 6  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are between 120bp and 130bp. The lanes contain the samples as 
follows; 1: TEC 93N, 2: TEC 93T, 3; TEC 94N, 4: TEC 94T, 5: TEC 95N, 6: TEC 95T, 7: TEC 96N, 
8: TEC 96T. All the samples were amplified by PCR and the PCR worked for all the samples shown 
in this figure. The amplification pattern was faint. Both alleles were protected for the samples TEC 
93N, 93T, 94N, 94T, 95N, 95T, 96N and 96T however, the intensities o f the alleles on the 
polyacrylamide gel were weak.
The study of allele loss for D17S776 using autoradiography is shown in Figure 3.4.1.2
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130bp
120bp
Figure 3.4.1.2: Autoradiography result of radioactively labelled PCR products of 
marker D17S776
The PCR products o f marker D 1 7 S 7 7 6  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are between 120bp and 130bp. The radioisotope used was a-^^P- 
dCTP.The lanes contain the samples as follows; 1: TEC 96N, 2: TEC 96T, 3; TEC 97N, 4: TEC 97T, 
5: TEC 98N, 6: TEC 98T. All the samples shown in this figure contained both of the alleles and allele 
loss in any o f the tumor samples could not be observed. No LOH was observed for any one o f the 
samples for the marker D I7 S 7 7 6 .
3.4.2 Assessment of D l 7S800 for Loss of Heterozygosity
D17S800 is another intragenic polymorphic marker used in order to study LOH. Its 
chromosomal localization is between D17S776 and D17S856. It has she different alleles 
with different allele frequencies. The lengths of these alleles vary between 0.168kb and 
0.178kb and the allele frequencies lie between 0.0500 and 0.4200. Allele 1 is the allele 
with the lowest allele frequency and has a frequency of 0.0500. In contrast allele 3 is 
the allele with highest allele frequency and has an allele frequency of 0.4200. That 
means that the likelihood of obtaining an allele fragment with a length of 0.168kb is 
lowest and with a length of 0.178kb is highest for the marker DI7S800.
By using both silver staining and autoradiography 16 tumors out of 18 of 9 individuals 
were studied. The appropriate lengths of PCR products were obtained. Both alleles
62
were observed in all the samples studied. No LOH was observed. The silver stained 
polyacrylamide gel of D17S800 alleles shown in Figure 3.4.2.1.
178bp
168bp
Figure 3.4.2.1: The silver stained polyacrylamide gel of D17S800 alleles
The PCR products of marker D 1 7 S 8 0 0  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are between 168bp and 178bp. The lanes contain the samples as 
follows; 1: TEC 98N, 2; TEC 98T1, 3: TEC 98T2, 4: TEC 98T3, 5: TEC lOON, 6: TEC lOOT, 7: 
TEC lOlN, 8: TEC lOlT. Both paternal and maternal alleles were observable in all o f the samples 
studied. The alleles of the sample TEC lOOT were observable in the polyacrylamide, however their 
banding patterns were very faint.
LOH study for the marker D17S800 by using radioactive labelled dNTPs is shown in 
Figure 3.4.2.2.
•  w w
Figure 3.4.2.2: Autoradiography result of radioactively labelled PCR products of 
marker D17S800
The PCR products o f marker D J 7 S 8 0 0  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are between 168bp and 178bp. The radioisotope used is a-^^P- 
dCTP. The lanes contain the samples as follows; 1: TEC lOlT, 2: TEC lOlN, 3: TEC lOOT, 4: TEC 
lOON, 5: TEC 99T, 6: TEC 99N, 7: TEC98T, 8: TEC 98N. All the samples shown in this figure 
contain both o f the alleles o f paternal and maternal origin. There were some problems with the PCR 
amplification o f the samples lOON, lOOT, 98N and 98T. Therefore the banding patterns of these 
samples on polyacrylamide gel were very faint. However the alleles o f these samples obtained were 
informative and sufficient to conclude that no LOH exists for their tumor samples.
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3.4.3 Assessment of D17S855 for Loss of Heterozygosity
D17S855 is an extragenic marker, which is very close to BRCAl. Therefore the loss of 
this marker might be important in determining whether a putative tumor suppressor 
gene could be localized to this region or not. It has seven different alleles with different 
allele frequencies. The lengths of these alleles vary between 0.143kb and 0.155kb. The 
allele frequencies lie between 0.0500 and 0.2600. Allele 1 and allele 7 are the alleles 
with the lowest allele frequencies and have a frequency of 0.0500. In contrast allele 6 
is the allele with highest allele frequency and has an allele frequency of 0.2600. That 
means that the likelihood of obtaining an allele fragment with a length of 0.143kb is the 
lowest and with a length of 0.145kb is is the highest for the marker DI7S855.
Through autoradiography and silver staining 14 out of 18 tumors in 9 out of ten 
individuals were investigated. The PCR amplification was performed successfully and 
expected banding patterns were observed in polyacrylamide gel. No LOH was 
observed in the samples. The silver stained polyacrylamide gel result of D17S855 is 
shown in Figure 3.4.3.1.
155bp 
143bp
Figure 3.4.3.1: The silver stained polyacrylamide gel o{D17S855 alleles
The PCR products o f marker D 1 7 S 8 5 5  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are about 143bp and 155bp. The lanes contain the samples as 
follows;
1: TEC 96N, 2: TEC 96T, 3; TEC 97N, 4: TEC 97T
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The study of LOH for the marker D17S855 by using radioactive labelled dNTPs is 
shown in Figure 3.4.3.2
I55bp
143bp
Figure 3.4.3.2: Autoradiography result of radioactively labelled PCR products of 
marker D17S855
The r c R  products o f marker D 1 7 S 8 5 5  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are about 143bp and 155bp. The radioisotope used is a-^“P-dCTP. 
The lanes contain the samples as follows;
1; TEC 91N, 2: TEC 91T, 3: TEC 93N, 4: TEC 93T1, 5; TEC 93T2, 6; TEC 93T3, 7: TEC94N,
8; TEC 94T
3.4.4 Assessment of D17S856 for Loss of Heterozygosity
D17S856 is another intragenic marker used for assessing LOH in BRCAl. It contains 
six alleles whose lengths differ between 0.228kb and 0.264kb. The values of allele 
frequencies lie between 0.0100 and 0.7700. Alleles 1 (0.001) and 6 (0.001) are the 
alleles with lowest frequencies. Allele 2 (0.7700) is the allele with the highest 
frequency.
In this study 15 out of 18 tumors in 9 out of 10 individuals were analyzed for LOH. In 
two samples, TEC 94 and TEC 99 LOH was found. LOH was seen both by using 
mutation detection enhancement (MDE) gel and routine non-denaturing 
polyacrylamide gel. The other samples did not show LOH. The banding patterns were 
in expected sizes and the loss of one allele in tumor samples were obviously observable 
in both gels.
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The LOH using silver stained non-denaturing polyacrylamide gel is shown in Figure 
3.4.4.2.
300bp
200bp
264bp
228bp
Figure 3.4.4.2: LOH in TEC 99 by non-denaturing polyacrylamide gel
The PCR products o f marker D 1 7 S 8 5 6  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The loss o f one allele was observed in TEC 99T (Lane 2). The size marker used is 
lOObp ladder (Lane M). The allele sizes are between 228bp and 264bp. The lanes contain the samples 
as follows; 1: TEC 99N, 2: TEC 99T, 3; TEC lOON, 4: TEC lOOT. All the samples shown in this 
figure are informative, both paternal and maternal alleles are present in normal tissues. In the tissue 
sample TEC 99T the loss o f one allele is observed and it is concluded that LOH has taken place for 
the sample TEC 99. The tumor tissue o f the other sample TEC 100, contained both of the alleles of 
maternal and paternal origin and no LOH was observed for this sample.
3.4.5 Assessment of D13S260 for Loss of Heterozygosity
D13S260 is one of the intragenic markers used in this study in order to find the LOH 
status in BRCA2. Its maximum heterozygosity is 0.7800 and it contains eight alleles. 
The existence of these two factors together makes D13S260 an ideal marker for LOH 
studies. The values of allele frequencies of DI3S260 are between 0.0357 and 0.4107. 
Alleles 6 and 8 share the property of having the minimum allele frequency with a 
frequency of 0.0357 and fragment length of 0.159kb. Allele 2 contains the maximum 
allele frequency of 0.4107 with a fragment length of 0.163kb.
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Only autoradiography was used to determine whether LOH has occurred in this 
marker or not. 17 out of 18 tumors in 10 individuals were studied. No LOH was 
observed in any of the tumors.
The assessment of LOH for D13S260 by using autoradiography that resulted in the 
absence of LOH for the samples TEC 96 N, 96T1, 96 T2, TEC 97N, 97T1, 97T2 and 
97 T3 are shown in Figure 3.4.5.
171bp
158bp
Figure 3.4.5.: Autoradiography result of radioactively labelled PCR products 
TEC 96 and TEC 97 of marker D13S260
The PCR products o f marker D 1 3 S 2 6 0  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are 158bp and 171bp. The radioisotope used is a-^¥-dCTP. The 
lanes contain the samples as follows;
1; TEC 96N, 2; TEC 96T1, 3: TEC 96T2, 4: TEC 97N, 5: TEC 97T1, 6; TEC 97T2, 7: TEC 97T3
3.4.6 Assessment of D13S267 for Loss of Heterozygosity
D13S267 is an extragenic marker localized very close to the BRCA2 gene. As it 
contains a heterozygosity value of 0.6879 and six alleles it serves as a useful marker 
for LOH studies. The allele frequencies vary between 0.0192 and 0.4423 with 
fragment lengths lying between 0.148kb and 0.162kb. Allele 2 has the highest allele 
frequency, and is the most common allele with a fragment length of 0.148kb. Allele six 
however is the allele with the lowest frequency but biggest fragment size.
6 8
All 18 tumors of ten individuals were studied for LOH status. Only autoradiography 
was used to determine allele loss. The banding patterns of the tumors were as expected 
and no allele loss was observed in the samples studied. However in the tumors of TEC 
98 it was observed that the intensities of the two alleles were not same. Although the 
intensities of both alleles in normal tissue of TEC 98 were same, in tumor tissues the 
amplification of one allele was obviously reduced. Due to these data it was suggested 
that LOH had occurred in TEC 98 tumor tissue samples.
The autoradiography in which allele loss was observed is shown in Figure 3 .4.6.1.
162bp
ISObp
Figure 3.4.6.1: Autoradiography result of TEC 98 PCR products of marker
D13S267
The PCR products of marker D 1 3 S 2 6 7  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are aboutl50bp and 162bp. The radioisotope used is a -P ’^ -dCTP. 
The lanes contain the samples as follows;
1: TEC 98N, 2: TEC 98T1, 3: TEC 98T2, 4: TEC 98T3
The LOH study using autoradiography in order to show allele loss in DJ3S260 is 
shown in Figure 3.4.6.2
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Figure 3.4.6.2; Autoradiography result of radioactively labelled PCR products of 
marker D13S267
The PCR products o f marker D 1 3 S 2 6 7  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are about 150bp and 162bp. The radioisotope used is a-^^P-dCTP. 
The lanes contain the samples as follows;
1; TEC 96N, 2; TEC 96T1, 3: TEC 96T2, 4: TEC 97N, 5; TEC 97T1, 6: TEC 97T2. The bands 
representing the amplification pattern o f TEC 96 T1 and 96 T2 were faint (Lanes 2 and 3).
3.4.7 Assessment of D13S289 for Loss of Heterozygosity
D13S289 is an intragenic marker within the gene BRCA2 with a maximum 
heterozygosity of 0.7400. This marker has eight alleles and the allele frequencies vary 
between 0.0536 and 0.4464. Allele 1 has the highest frequency of 0.4464. Alleles 3, 4 
and 8 share the same lowest frequency of 0.0536.
13 out of 18 tumors in 7 out of 10 individuals were investigated for LOH. Only 
autoradiography was used to determine allele loss. In one of them (TEC 96) LOH was 
observed. The other samples did not show allele loss for the marker D13S289.
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The LOH study using autoradiography in order to show allele loss in D13S289 is 
shown in Figure 3 .4.7
3 4 5 6 7 8 9 10 11 12 13 14
+ + : 276bp
260bp
Figure 3.4.7: Autoradiography result of radioactively labelled PCR products of 
mailier D13S289
The PCR products o f marker D 1 3 S 2 8 9  were run on an 8% non-denaturing polyacrylamide gel to 
separate the alleles. The allele sizes are about 260bp and 276bp. The loss o f one allele was observed in 
TEC 96T1 and 96T2 (Lane 11 and lane 12) The radioisotope used is a-^^P-dCTP. The lanes contain 
the samples as follows;
1: TEC 93N, 2; TEC 93T1, 3: TEC 93T2, 4; TEC 93T3, 5: TEC 94N, 6: TEC 94T, 7: TEC 95N,
8; TEC95T1, 9: TEC 95T2, 10: TEC 96N, 11: TEC 96T1, 12: TEC 96T2, 13: TEC lOON,
14: TEC lOOT
3.4.8 Assessment of PTEN  for Loss of Heterozygosity
PTEN is a newly identified gene. Therefore no studies are available on the alleles and 
allele frequencies of PTEN. It is only known that the marker used in this study is an 
intragenic marker and it amplifies a fragment length of minimum 0.154kb.
All 18 tumors of 10 individuals were analysed for LOH with the silver staining method. 
No LOH was observed in the samples studied.
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Silver staining method was used to show allele loss in PriSA/^  (Figure 3.4.8)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
I64bp
154bp
Figure 3.4.8: The silver stained polyacrylamide gel of PTEN  alleles
The PCR products o f marker P T E N  were run on an 8% non-denaturing polyacrylamide gel to separate 
the alleles. The size marker used is pUC mix marker (Lane 1). The allele sizes are 154bp and 164bp. 
The lanes contain the samples as follows;
1: Marker, 2: TEC 91N, 3: TEC 91T, 4: TEC 93N, 5: TEC 93T1, 6; TEC 93T2, 7: TEC 93T3,
8: TEC94N, 9: TEC 94T, 10: TEC 95N, 11: TEC 95T1, 12: TEC 95T2, 13: TEC 96N,
14: TEC 96T1, 15: TEC 96T2
The results of this study for each marker are summarized in Tables 3.4.1, 3.4.2, 3.4.3, 
3.4.4, 3.4.5, 3.4.6, 3.4.7 and 3.4.8.
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Table 3.4.1: Results o f LOH study for the m arker D17S776
1 GENE B R C A 1
MARKER D I7 S 7 7 6
POLYM ORPHISM CA DINUCLEOTIDE
CHROM OSOM AL LOCALIZATION 17pter-17qter
MAXIMUM HETEROZYGOSITY 0.4000
PRIMER NAME TC 140/93
FORWARD PRIM ER SEQUENCE TCCATGACCCTATGGACCA
REVERSE PRIM ER SEQUENCE AAACCTCTGTCTCTTTGCAG
AMPLIFIED SEQUENCE MINIMUM LENGTH 0.120kb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0.130kb
SAMPLE LOSS OF HETEROZYGOSITY
TEC 91T -
TEC 93T1 ND
TEC 93T2 ND
TEC 93 T3 ND
TEC94T -
TEC 95T1 -
TEC 95T2 ND
TEC 96T1 -
TEC 96T2 -
TEC 97T1 -
TEC 97T2 -
TEC 97T3 -
TEC 98T1 -
TEC 98T2 -
TEC 98T3 -
TEC 99T -
TEC lOOT -
TEC lOlT ND
-  ; No LOH was observed
ND: The samples in which the result was not determined
13 out o f 18 tumors in 9 out of 10 individuals were studied for their LOH status. In none of them
allele loss was observed.
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Table 3.4.2: Results of LOH study for the marker D17S800
1 GENE f iR C A l
MARKER D 1 7S 800
POLYMORPHISM CA DINUCLEOTIDE
CHROM OSOM AL LOCALIZATION 17pter-17qter
MAXIMUM HETEROZYGOSITY 0.7433
PRIM ER NAME TC 155/156
FORWARD PRIM ER SEQUENCE GGTCTCATCCATCAGGTTTT
REVERSE PRIM ER SEQUENCE ATAGACTGTGTACTGGGCATTGA
AMPLIFIED SEQUENCE M INIMUM LENGTH 0.168kb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0.178kb
SAMPLE LOSS OF HETEROZYGOSITY
TEC91T -
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC94T -
TEC 95T1 -
TEC 95T2 -
TEC 96T1 ND
TEC 96T2 ND
TEC 97T1 -
TEC 97T2 -
TEC97T3 -
TEC 98T1 -
TEC 98T2 -
TEC 98T3 -
TEC 99T -
TEC lOOT -
TEC 10 IT -
-  : No LOH was observed
ND; The samples in which the result was not determined
16 out o f 18 tumor tissue samples in 9 out o f 10 individuals were studied for their LOH status. In none
of them LOH was observed.
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Table 3.4.3: Results of LOH study for the marker D17S855
GENE i m c A i
MARKER D 1 7S 855
POLYMORPHISM CA DINUCLEOTIDE
CHROMOSOMAL LOCALIZATION ___________________m ___________________
MAXIMUM HETEROZYGOSITY 0.8220
PRIMER NAME TC 94/139
FORWARD PRIMER SEQUENCE GGATGGCCTTTTGAAAAGTGG
REVERSE PRIMER SEQUENCE ACACAGACTTGTCCTACTGCC
AMPLIFIED SEQUENCE MINIMUM LENGTH 0.143kb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 1 0.155kb
SAMPLE LOSS OF HETEROZYGOSITY
TEC 9 IT -
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC94T -
TEC 95T1 -
TEC 95T2 -
TEC 96T1 -
TEC 96T2 ND
TEC 97T1 -
TEC 97T2 ND
TEC 97T3 ND
TEC 98T1 -
TEC 98T2 -
TEC 98T3 -
TEC99T -
TEC lOOT -
TEC lOlT ND
-  : No LOH was observed
ND: The samples in which the result was not determined
14 out o f 18 tumors o f 9 out of ten patients were studied for their LOH status. In none of them LOH
observed. In TEC 101 PCR amplification did not work and no result was obtained.was
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Table 3,4.4: Results of LOH study for the D17S856
1 GENE B R C A I
MARKER D I7 S 8 5 6
POLYMORPHISM TETRANUCLEOTIDE
CHROMOSOMAL LOCALIZATION ........... Щ
MAXIMUM HETEROZYGOSITY 0.3891
PRIMER NAME TEC 137/138
FORWARD PRIMER SEQUENCE AAGGCAAGACTTCGTCGAGA
REVERSE PRIMER SEQUENCE CATTCCCTGGTCCTGTGC
AMPLIFIED SEQUENCE MINIMUM LENGTH 0.228kb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0.264kb
SAMPLE LOSS OF HETEROZYGOSITY
TEC 91T -
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC 94T +
TEC 95T1
TEC 95T2 ND
TCC 96T1 -
TEC 96T2 ND
TEC 97T1 -
TEC 97T2 -
TEC97T3 -
TEC 98T1 -
TEC 98T2 -
TEC 98T3 -
TEC 99T -l·
TEC lOOT -
TEC lOlT ND
-  : No LOH was observed 
+ : LOH was observed
ND; The samples in which the result was not determined
15 out of 18 tumors in 9 out of 10 patients were studied for LOH in the marker D 17S 856 . In two 
tumor samples TEC 94T and TEC 99T the loss o f one allele was observed. In other tumor samples no 
LOH was observed. The PCR amplification and polyacrylamide gel electrophopresis did not work for 
the sample TEC 101.
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Table 3.4.5: Results of LOH study for the marker D13S260
i GENE i m c A i
MARKER D I3 S 2 6 0
POLYMORPHISM CA DINUCLEOTIDE
CHROM OSOM AL LOCALIZATION ___________________m ___________________
M AXIMUM HETEROZYGOSITY 0.7800
PRIM ER NAME TC 195/196
FORWARD PRIM ER SEQUENCE AGATATTGTCTCCGTTCCAAGA
REVERSE PRIMER SEQUENCE CCCAGATATAAGGACCTGGTTA
AMPLIFIED SEQUENCE MINIMUM LENGTH 0.159kb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0.171kb
SAMPLE LOSS OF HETEROZYGOSITY
TEC91T -
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC 94T -
TEC 95T1 -
TEC 95T2 -
TEC 96T1 -
TEC 96T2 -
TEC97T1 -
TEC97T2 -
TEC 97T3 -
TEC 98T1 -
TEC 98T2
TEC 98T3 ND
TEC99T -
TEC lOOT -
TEC lOlT -
-  : No LOH was observed
ND: The samples in which the result was not determined
17 out o f 18 tumors o f all individuals were studied In none of the tumors studied LOH was found.
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Table 3.4.6: Results of LOH study for the marker Z)/5iS267
1  GENE B R C A l
MARKER D J 3 S 2 6 7
POLYM ORPHISM CA DINUCLEOTIDE
CHROM OSOM AL LOCALIZATION 13q
MAXIMUM HETEROZYGOSITY 0.6900
PRIMER NAME TC I9I/I92
FORWARD PRIM ER SEQUENCE GGCCTGAAAGGTATCCTC
REVERSE PRIM ER SEQUENCE TCCCACCATAAGCACAAG
AMPLIFIED SEQUENCE MINIMUM LENGTH O.ISOkb
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0.162bp
SAMPLE LOSS OF HETEROZYGOSITY
TEC91T —
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC 94T
TEC 95T1
TEC 95T2 -
TEC 96T1 -
TEC 96T2 -
TEC 97T1 -
TEC 97T2 -
TEC 97T3 -
TEC 98T1 +
TEC 98T2
TEC 98T3 +
TEC 99T -
TEC lOOT -
TEC lOlT -
-  : No LOH was observed 
+ : LOH was observed
ND: The samples in which the result was not determined
All 18 tumor samples are studied for LOH. In three tumor tissue samples o f one individual (TEC 
98T1, T2 and T3) it was seen that the allele intensities were different although the intensities in the 
normal sample of the same individual was same. Therefore it was concluded that LOH had occurred 
in TEC 98T1, T2 and T3. In other samples no LOH for the marker D 1 3 S 2 6 7  was observed.
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Table 3.4.7: Results of LOH study for the m&rVxr D 13S289
-  : No LOH was observed 
+ : LOH was observed
ND: The samples in which the result was not determined 
UI: Uninformative
Seven out o f ten individuals and 13 out of 18 tumors were studied for LOH. In two tinnor variants of 
TEC 96 (TEC 96T1 and TEC 96T2) LOH were observed. The PCR amplifications and 
polyacrylamide gel electrophoresis o f the samples TEC 98, TEC 99 and TEC 101 have been done 
however no results were obtained. In TEC 95 the strong amplification o f one band in both normal and 
tumor tissue samples was observed and this is suggested as an uninformative case.
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Table 3.4.8: Results of LOH study for the marker PTEN
1 GENE
MARKER P T E N
POLYM ORPHISM CA DINUCLEOTIDE
CHROM OSOM AL LOCALIZATION ___________________ Ш ___________________
M AXIMUM HETEROZYGOSITY Not known
PRIM ER NAME P T E N  F/R
_________ FORWARD PRIMER SEQUENCE_________ AAATGTACGGTTCATTGACTT
REVERSE PRIM ER SEQUENCE GACTGACTACAAATGGGCA
AMPLIFIED SEQUENCE MINIMUM LENGTH 0.154bp
AMPLIFIED SEQUENCE MAXIMUM LENGTH 0 .164bp
SAMPLE LOSS OF HETEROZYGOSITY
TEC 91T -
TEC 93T1 -
TEC 93T2 -
TEC93 T3 -
TEC94T -
TEC 95T1 -
TEC 95T2 -
TEC 96T1 -
TEC 96T2 -
TEC 97T1 -
TEC97T2 -
TEC 97T3 -
TEC 98T1 -
TEC 98T2 -
TEC 98T3 -
TEC 99T -
TEC lOOT -
TEC lOlT —
-  : No LOH was observed
All 18 tumor samples are studied for LOH. In none o f them LOH was found.
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The results of the whole study is summarized in Table 3.4.9
Table 3.4.9: Results of the LOH study for the genes BRCAl, BRCA2 and PTEN
1 LOH D 17S~  76 D I7 S S 0 0 D17HH5> n i:^ ss 5 6 /) l.yS 2 6 0 D I3 S 2 6 7 D I 3 S : s 9 p m \
TEC 91T - - - - - - - -
TEC 93T1 ND - - - - - - -
TEC 93T2 ND - - - - - - -
TEC 93T3 ND - - - - - - -
TEC 94T - - - + - - - -
TEC95T1 - - - - - - UI -
TEC95T2 ND ND \ ND i - UI -
TEC 96T1 - ND 1 - - - - + -
TEC 96T2 - - ND ND - - + -
TEC 97T1 - - - - - - - -
TEC 97T2 - ND - - - -
TEC 97T3 - - ND - - - - -
TEC 98T1 - - - - - + ND -
TEC 98T2 - - - - - + ND -
TEC 98T3 - - - - ND + ND -
TEC 99T - - - - - ND -
TEC lOOT - - - - - - - -
TEC 10 IT ND - ND - - - ND -
-  : No LOH was observed 
+ ; LOH was observed
ND: The samples in which the result was not determined 
UI; Uninformative
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In this study, three genes BRCAl, BRCA2 and PTEN are studied for their LOH status 
in testis cancer. Eight highly polymorphic intragenic and extragenic markers are used 
to investigate the allele losses in these genes.
The LOH within BRCA1 is observed in two samples TEC 93 and TEC 99 by using the 
marker D17S856. The other samples did not show LOH for any marker used to study 
BRCAl. Two out of ten individuals showed LOH for D17S856 and this value is 
suggested to be considerable to study the relation between testis cancer and LOH.
The LOH within BRCAl is observed in three histological variants of TEC 98 (TEC 
98TLT2 and T3) by using the marker D13S267 and two histological variants of TEC 
96 (TEC 96T1 and T2) by using the marker D13S289. In D13S267, due to the 
difference in allele intensities between the normal and tumor tissues and in DI3S289, 
due to the obvious allele loss it is suggested that LOH has been occurred. Also for 
BRCAl, the LOH values observed are suggested to be important to study the relation 
between BRCAl and LOH.
By increasing the sample number and the number of the markers used, the LOH status 
for BRCAl, BRCAl and PTEN might be further assessed and statistically more 
considerable results might be obtained.
3.5 CONCLUSION
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CHAPTER 4. DISCUSSION
Because of its considerable death rate (20-30%), testis cancer might be accepted as a 
severe health problem for young men between the ages of 15-34. The significantly 
high lifetime prevalence of 4.9/100000 and variable incidence of testis cancer among 
different populations suggests that the studies of testis cancer have also a social side. 
Molecular studies would therefore be of great importance as they provide the 
necessary information to understand the causative mechanisms underlying this 
disease.
There is no data about the incidence of testis cancer in Turkey. Turkish population is a 
young population where testis cancer might be an important threat. The various status 
of industrialization in several regions of Turkey might be another reason to study 
testis cancer since it is thought that this disease also has an environmental basis. How 
these environmental factors act in molecular manner and which molecular 
mechanisms might be involved in the progression of testis cancer are questions that 
are waiting to be enlightened.
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Worldwide, in molecular terms, testis cancer is not studied very frequently because of 
its high cure rate. This situation is also same for Turkey. All the factors mentioned 
above make the study of testis cancer desirable.
Several studies have revealed that distinct molecular alterations such as 
isochromosome 12 existence, trisomies, deletions, duplications, and other 
rearrangements of particular chromosomes, oncogene overexpressions and allele 
losses of some tumor suppressor genes are characteristic in testis cancer. Allele loss 
was known to be the key pointer in the existence of tumor suppressor genes and 
therefore LOH analyses were thought to be the most appropriate approach to analyse 
tumor suppressor genes. Some chromosomes were found to be more susceptible to 
allele losses in testis cancer and the tumor suppressor gene analyses studies were 
focused on these chromosomes. Chrosomes 10, 13 and 17 are a:mong the 
chromosomes in which allele losses are very frequent (Looijenga et a l, 1994). This 
study was therefore focused on the analysis of tumor suppressor genes localized 
within these chromosomes. PTEN is a tumor suppressor gene recently identified and 
localized to chromosome 10. It was known that the allele loss of this gene was 
observable in three related diseases (Myers et al., 1997). It was also shown that the 
allele loss of PTEN occurred in advanced prostate cancers (Marsh et al., 1997). 
Therefore it was thought that this gene might also be involved in testis cancer and the 
allele loss of this gene was studied to analyse loss of heterozygosity. The second gene 
selected in this study for analysis was BRCAl. BRCAl is a gene whose LOH was 
shown in significant proportions in many cancers such as prostate cancer, breast 
cancer and ovarian cancer. The fact that the allele loss within this gene existed in 
many cancers and the high expression of this gene in testicular tissue made BRCA1 a
84
strong candidate for this study. The last gene analysed in this study was BRCA2. The 
chromosomal localization o f the gene and its relation with BRCA1 made this gene 
important for this study. The most important fact for the study of these three genes 
was that LOH studies for those genes were not performed for testis cancer previously.
The patients selected for this study were nonseminomatous stage EC and stage EIC 
patients. Nonseminomatous histology exhibits lower differentiation however 
seminomatous cells are much more differentiated in comparison to nonseminomatous 
cells. Nonseminomatous cases are much more severe than seminomatous cases. In 
order to find the underlying factors of testis cancer at the beginning of the disease and 
to treat it as early as possible and to develop molecular methods providing this aim, it 
was thought that it would be more useful to analyse nonseminomatous patient samples 
instead of seminomatous cases.
It is known that several mechanisms might result in LOH. Through mutation analysis 
studies it might be investigated which mechanisms leading to LOH are much more 
frequent in testis cancer. Pure LOH based studies were not sufficient to decide for 
which mechanism causing LOH might be involved in the allele loss. The 
determination of the mechanism leading to LOH requires mutation detection analysis. 
However LOH studies are necessary in order to initiate mutation detection studies of 
tumor suppressor genes. It is possible to come across situations in which LOH occurs 
but mutation does not exist. However, there is not any case reported in which 
mutation in an allele has occurred without the existence of LOH. Therefore the best 
approach to investigate tumor suppressor genes might be to begin with LOH studies 
and continue with mutation detection analyses.
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The informativeness of polymorphic markers is especially important in LOH studies. 
The distance of the polymorphic marker used to the gene of interest, allele number 
and frequency of the polymorphic marker are the important factors in choosing the 
ideal marker. Once markers are chosen it might be concluded whether a putative 
tumor suppressor gene exists in the area of interest or the allele loss has occurred in 
the tumor suppressor gene of interest. The polymorphic markers used in this study 
contained both low and high PIC values. Those that contain low PIC values were 
useful because they were intragenic markers and the loss of these markers were 
sufficient to determine the loss of the allele without the need of a high PIC value. The 
reason for using both intragenic and extragenic markers is again to determine the 
existence of a putative tumor suppressor gene or allele loss within the gene analysed.
This study was done on 10 individuals. The samples of these individuals were from 
the archives of Hacettepe University Pathology Department. The samples were 
paraffin embedded and old and thus the DNA could not be isolated in intact form. 
Another reason for this could be the fixative the samples were embedded in. Although 
the DNA could not be isolated intact, it could be successfully amplified by PCR. It 
was thought that this was due to the small fragment length of the sequences amplified.
Three genes were analysed in the existence of eight polymorphic markers in this 
study. Ten patients were investigated for LOH status. Both intragenic and extragenic 
markers were used to investigate the presence of a putative tumor suppressor gene 
around or LOH within BRCAl and BRCA2 genes. The markers, D17S776, D17S800, 
D17S855 and D17S856 were used for investigating BRCAl gene. The distance 
between the markers selected was approximately 250-300 kilobases and an average of
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one polymorphism every 60 kilobases was represented. The markers D13S260, 
D13S267 and D13S289 were used to determine the LOH status in BRCA2. PTEN v^ diS 
typed in the existence of a single intragenic marker and investigated for its LOH 
status.
In this study it was found that BRCA1 gene had undergone allele loss for the marker 
D17S856 in 2 out of 10 individuals. These patients were TEC 94 and TEC 99. The 
proportion of allele loss accounts for 20% which is a significant ratio. Loss within this 
intragenic marker directly indicates the loss of the allele within BRCA 1. Patient TEC 
94 showing LOH had embryonal carcinoma histology. This patient is dead probably 
due to the aggressive character and totipotential capacity of this histology. The other 
patient TEC 99 had mature teratoma histology. Since mature teratomas contain a 
collection of differentiated cell types the risk of having a genetic alteration is higher 
than in a single cell type histology. The other markers did not show any allele loss. 
This might be because of the loss of a very small area or a point mutation within the 
gene or the distance of the markers to each other. Even though the markers used were 
very close to each other the deletion might be so small that it does not affect the other 
markers used for the analvsis.
BRCA2 gene was also assessed for its LOH status. Interesting results were obtained 
by the LOH study o i BRCA2. In patient TEC 98, due to the difference in two allele 
banding patterns of tumor tissues it was suggested that one of the alleles was not 
amplified strongly as its homolog counterpart by using the polymorphic marker 
D13S267. However the intensity of two homolog alleles in the normal tissue of the 
sample did not show any difference. Since there was a quantitative change in the
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existence of one allele in tumor tissues, it was thought that an allele loss had occurred 
in the tumor samples of patient TEC 98. Patient TEC 98 had mix germ cell histology 
consisting of teratocarcinomas and yolk sac tumors.
LOH was found also in patient TEC 96 for the marker D13S289. Here one of the two 
alleles was lost and therefore it was suggested that LOH had occurred in the tumors of 
TEC 96. Patient TEC 96 exhibited mix germ cell histology consisting of 
teratocarcinoma, seminoma and embryonal carcinoma histologies. The aggressive and 
totipotential character of embryonal carcinoma, the property of teratoma being prone 
to contain various histologies together might increase the risk for a genetic alteration.
PTEN is a newly identified gene. The loss of its alleles is shown in advanced cancer. 
The chromosome PTEN located in is prone to allele losses. These factors together 
make the LOH studies for PTEN desirable. The number of polymorphic markers 
found for PTEN is low. The LOH studies will extend with the increase of the numbers 
of polymorphic markers. PTEN was assessed only by using one marker. This marker 
was intragenic and the absence of this marker was an important indicator in the 
presence of LOH. However PTEN should be analysed by extending the number of 
markers and final suggestion should be done after the analyses by using additional 
markers.
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FUTURE PERSPECTIVES
- The study was performed on 10 individuals. 18 histological variants of these 10 
individuals were investigated for their LOH status. The next step would be to 
continue the study by increasing the number of patients studied.
- Mutation detection analyses for the samples in which LOH was found might be 
performed. Single stranded conformational polymorphism analysis or 
heteroduplex analyses might be carried out in order to determine whether a 
mutation has occurred within the gene or not.
Sequencing might be performed for the samples where the intensity differences 
were observed to determine whether a point mutation might be the mechanism 
resulting in the generation of LOH.
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